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Abstract 
The revolutionary development of soft ionization techniques like matrix-assisted laser 
desorption/ionization (MALDI) has opened up the possibilities for mass spectrometry (MS) in 
protein detection, identification, and sequencing. The ability of MALDI MS to acquire images 
of intact tissue sections offer an additional dimension of analysis where location information 
can be attained. Visualization of biological systems help to unravel the complexities of cells, 
drug pathways, and disease pathology. However, the capabilities of MALDI MS imaging are 
often being questioned, as signals are typically biased towards the most abundant component 
within a complex sample. Within biological tissue samples, the most abundant components are 
salts and lipids making it difficult for compounds such as proteins and peptides to ionize and 
be detected.  
In this thesis, sample preparation techniques are investigated to help improve the detection 
sensitivity of MALDI MSI for proteins and peptides through investigation of ZP1609 and the 
amyloid ß (Aß) protein. ZP1609 is an antiarrhythmic drug designed to protect against cardiac 
ischemia-reperfusion injury, and Aß oligomers are strongly correlated with Alzheimer’s 
disease (AD) pathology. Both of which are considered lower abundance compounds within 
samples analyzed, and therefore ideal candidates for the work described herein. This thesis 
presents MALDI MS capabilities in the detection of noncovalent complexes by distinguishing 
variations in in vitro Aß composition for different sample preparatory procedures. 
Furthermore, a reduction in ion suppression effects by salts and lipids was demonstrated with 
increased MALDI MSI detection sensitivity for the target peptide. Most noticeably, an 
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additional acidification protocol generated images of greater detection sensitivity, and spatial 
resolution. Introduction of solid-phase extraction (SPE) by means of magnetic bead application 
was designed to improve the extraction of proteins from tissue sections. The C18 
functionalized magnetic beads provided signal enhancement capabilities for varying 
concentrations of Aß1-42 samples, however difficulties were encountered when applied for 
MALDI MSI analysis. Nonetheless, the application of SPE for targeted analyte extraction prior 
to MALDI MS analysis was beneficial in improving detection sensitivity of Aß proteins with 
and without the presence of contaminants from tissue sections.  
 
 
 
 
 
 
 
Keywords 
MALDI TOF MS, MALDI MSI, Alzheimer’s disease, amyloid beta oligomers, matrix 
application, detection sensitivity, protein imaging, peptide imaging, solid-phase extraction, 
magnetic beads. 
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1.1 Overview of Protein Analysis 
1.1.1 Amino Acid Building Blocks 
As building blocks of cellular systems, proteins play a critical role in the structure, function, 
and regulation of biological systems. They are comprised of 20 naturally occurring amino 
acid residues with molecular weights ranging from 57 – 186 Da. These residues group 
together to form polypeptide chains predetermined by the genetic code. As indicated in 
Table 1.1, amino acids can be classified as either polar, or nonpolar based on the side chain 
composition [1-3]. Having awareness of the polarity of each residue helps to understand 
the hydrophobicity of amino acids, and in turn, predict the resulting protein structure. 
However, there is controversy surrounding the level of hydrophobic properties each residue 
possesses. Variations exist because of the difference in methods used to assess the relative 
hydrophobicity of each amino acid residue [4-7]. The measure of hydrophobicity is often 
achieved through either examination of the 3D protein structure, or by looking at the 
physical properties of the sidechains and observing how the amino acid partitions in water 
versus nonpolar solvent environments. Differences in the results obtained occurs when two 
different methods are used. Since the former evaluates the amino acid as part of a 
polypeptide chain, while the latter looks at the free amino acid residues, the two methods 
yield different results for residues that possess levels of opposing properties. In addition to 
the differences in evaluation, hydrophobic properties of the 20 amino acid residues is a 
relative unit of measure. Alternative factors such as the surrounding environment also play 
a role in the hydrophobicity of the amino acid. The polarity and hydrophobic properties of 
24 
 
cysteine and tyrosine at times are a topic of controversy. Cysteine possesses an –SH group 
which makes it a polar amino acid residue, but when investigating the 3D structure of 
proteins, cysteine is often found embedded within the core of the protein leading to 
misinterpretation that it is hydrophobic. However, this behaviour can be a result of the 
residue’s affinity to form disulfide bonds found in the core of the protein. Alternatively, 
tyrosine is an aromatic amino acid, and therefore should be considered nonpolar [2, 8]. 
Despite the aromatic ring, tyrosine also possesses an- OH group, and its contributions 
towards hydrogen bonding causes conflicting results when the level of hydrophobicity is 
assessed in different environments. For the purposes of the work described here, both 
cysteine and tyrosine will be regarded as a polar amino acid residues. 
  
25 
 
 
Table 1.1  Amino acid residues are listed with both the 3- and 1- letter symbols associated 
with each. The polarity of each amino acid has been provided. 
 
Amino Acid 
3-Letter 
Symbol 
1-Letter 
Symbol 
Polarity 
Alanine Ala A Nonpolar 
Arginine Arg R Polar 
Asparagine Asn N Polar 
Aspartic Acid Asp D Polar 
Cysteine Cys C Polar 
Glutamic Acid Glu E Polar 
Glutamine Gln Q Polar 
Glycine Gly G Nonpolar 
Histidine His H Polar 
Isoleucine Ile I Nonpolar 
Leucine Leu L Nonpolar 
Lysine Lys K Polar 
Methionine Met M Nonpolar 
Phenylalanine Phe F Nonpolar 
Proline Pro P Nonpolar 
Serine Ser S Polar 
Threonine Thr T Polar 
Tryptophan Trp W Nonpolar 
Tyrosine Tyr Y Polar 
Valine Val V Nonpolar 
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1.1.2 Protein Structure 
Amino acids join together through a condensation reaction with the amino group of one 
amino acid, and the carboxyl group of the other. This reaction releases water, forming the 
backbone of polypeptide chains. This unique backbone has minimal intrinsic mobility due 
to the partial double bond characteristics it possesses [2, 9]. The α-helical or ß sheet 
secondary structure of a polypeptide chain is generated through intra- and inter-strand 
hydrogen bonding respectively. The α helix conformation is developed when hydrogen 
bonding occurs between the carbonyl and the amino group of an amino acid four residues 
away in the polypeptide sequence [10]. The ß sheet structure is generated when hydrogen 
bonding occurs between the NH and CO groups of amino acids in different polypeptide 
chains. The formation of ß sheets can be in both anti-parallel or parallel orientations. 
After formation of the secondary structure, these proteins then fold and bend to form the 
three dimensional tertiary structure. At this stage, structural formation is determined 
primarily from the amino acid sequence. However, the protein’s environmental 
surroundings also play a key role in structural formation. Proteins will acquire the tertiary 
structure which provides the greatest stability, and in turn, the lowest energy state. In 
general, amino acids with hydrophobic side-chains will be buried within the protein 
structure, while the polar amino acids reside on the surface. In comparison to the secondary 
form, the tertiary structure of proteins appear to be irregular and unstructured. However, 
these three dimensional formations are developed and stabilized by the interactions 
between amino acid side-chains, and the hydrophobic backbone [11-12]. These interactions 
27 
 
include, hydrogen bonding, and the formation of salt or disulfide bridges. Protein 
quaternary structures then reflect the interaction between globular protein subunits which 
aggregate and develop into larger protein complexes.  
 
1.1.3 Biological Functions & Interactions of Proteins 
Based on just 20 different amino acid building blocks, countless proteins that serve key 
roles in structure, function and transport for all biological systems are generated. They can 
be categorized as antibodies, assembly proteins, blood proteins, enzymes, hormones, 
membrane proteins, or nucleoproteins. In attempts to understand biological systems, a 
growing list of protein interactions continue to be uncovered year after year. The majority 
of protein interactions are identified as protein-protein interactions (PPI), but interactions 
also exist between protein-lipids (often involving membrane proteins), and proteins with 
carbohydrates.  
Studying PPI can help researchers in furthering the understanding of protein function. The 
nature of the interaction differs depending on the protein affinity, composition, as well as 
whether the interaction is permanent or transient [13]. The key driving force in these 
interactions involve the protein concentration within a system, and the free energy of the 
complex in comparison to the energy of the protein in alternative states. PPI can be 
distinguished based on the structural and functional groups of the proteins involved, and 
the physical characteristics of the interaction. Complexes are considered either obligate, or 
non-obligate [13-14]. Where the former does not exists in vivo as stable structures, and the 
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latter can be found in vivo as stable, independent complexes. Alternatively, protein 
interactions are also classified as transient or permanent based on the lifetime of the 
resulting complex. Aside from PPI, lipid-protein interactions encompass another division 
that is integral in the functionality of biological systems as a whole. Lipids play a key role 
in the unique functionality, and physical properties of cellular membranes [15-17]. This 
type of interaction can be characterized as integral membrane proteins, peripheral 
membrane proteins, and soluble protein interactions [18-21].  
 
1.2 Protein Analysis 
Understanding the physical and chemical properties of proteins helps to elucidate 
biological systems and processes. This investigation involves identifying the molecular 
weight of proteins, studying the amino acid sequence, analyzing the 3D structure, 
understanding protein interactions, and to obtain location information for the presence of 
proteins within a biological tissue sample. Since protein functions are highly dependent on 
their structure, the study of intact proteins has become a primary target for many 
researchers [22-24]. With advancements in analytical techniques, researchers are now able 
to study intact protein structures, expression, and interactions. This information can aid the 
understanding of disease pathology to facilitate the development of therapeutics, detection 
of disease development, and possible preventative measures. 
Continuous development in analytical techniques provided additional platforms for the 
investigation of protein characteristics. X-ray crystallography, nuclear magnetic resonance 
(NMR), and electron microscopy are popular methods for the anlaysis of the 3D structure 
29 
 
of proteins. Alternatively, chemical crosslinking, fluorescence resonance energy transfer 
(FRET), and protein arrays are often used for studying protein interactions [25-31]. 
Proteomic research is an exponentially growing field of study, continuously expanding 
based on the development of available techniques. A large area of interest resides in protein 
identification within biological systems through the separation and detection of proteins 
based on molecular weight and sequencing. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and mass spectrometry are commonly used techniques in the 
separation and identification of proteins. SDS-PAGE is capable of isolating target proteins 
or peptides using electrophoresis. Application of SDS denatures the protein sample while 
providing an environment with a negative net charge. The proteins within the mixture then 
separate as they travel towards the anode. The negative environment disrupts the complex 
structures of proteins so the rate at which proteins travel is predominantly based on the 
molecular mass of the polypeptide.  
SDS-PAGE is an effective technique in identifying proteins for targeted approaches, 
however mass spectrometry (MS) provides a method to perform targeted and untargeted 
analysis of a wide range of molecules. This technique only requires microliter amounts of 
sample for analysis, and does not need the addition of dyes or antibodies for detection. 
Conventional ionization techniques, chemical ionization (CI), electron ionization (EI), and 
fast atom bombardment (FAB) limited MS to small, thermostable compounds. These 
ionization techniques resulted in severe fragmentation of relatively larger molecules which 
generated complex spectra that is difficult to interpret. In the late 1980s, development of 
two ionization techniques, electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) made MS available for analysis of larger molecules such 
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as proteins [22]. These two ionization techniques reduces the fragmentation of larger 
molecules, and therefore retains the original, intact molecule during the ionization process 
making it possible to directly study larger peptides and even intact proteins. 
The development of imaging techniques provided a methodology to obtain location 
information for target proteins. Traditionally, staining and labelling techniques such as, 
immunohistochemistry (IHC), magnetic resonance imaging (MRI), fluorescence 
microscopy, and positron emission tomography (PET) were used for targeted identification 
of proteins within biological systems. Although effective, these techniques are dependent 
on the successful staining or labelling of target molecules, and therefore successful 
localization of these proteins are directly affected by the specificity of the stains and labels 
used.  
Introduction of matrix-assisted laser desorption/ionization mass spectrometry imaging 
(MALDI MSI) presented a powerful technique which provides two dimensional 
information regarding target samples. This platform is not only capable of the 
characterization and identification of proteins and complex molecules, but it also possesses 
the ability to map out protein expression within intact tissue sections. Similar to standard 
MALDI MS analysis, information is extracted as the laser hits the matrix coated sample. 
As the laser moves along the tissue section, each ablation spot allows for information to be 
extracted and acts as “pixels” for the image generated.  This method of analysis provides 
information regarding protein expression within a biological sample, which would 
typically be lost in standard protein extraction, purification or separation protocols. 
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1.3 Theory and Instrumentation for Mass Spectrometry 
1.3.1 Instrumentation for Mass Spectrometry 
Mass spectrometry has come a long way since the development of the first instrument by 
Sir J. J. Thomson [32-33]. As the instrument matured, its capabilities continues to expand 
beyond a tool for physicists. From initially detecting the charge-to-mass (e/m) for particles 
such as electrons, to the ongoing expansion of applications in all fields of science. Overall, 
three processes occur in mass spectrometers, ion generation, separation, and detection. 
These three processes are achieved using an ion source, mass analyzer, and the ion detector 
respectively.  
The ion source is where sample ions are generated. A variety of ionization sources are 
available, with the most prominent ones in proteomic research being electrospray 
ionization (ESI), and matrix-assisted laser desorption/ionization (MALDI). These “soft” 
ionization systems produce ions with minimal fragmentation, therefore providing intact 
gaseous sample ions for analysis of larger biomolecules. The ions generated are then 
transferred to the mass analyzer, where they are separated based on their mass-to-charge 
ratios (m/z). The five most commonly use mass analyzers are, time-of-flight (TOF), 
quadrupole (Q), quadrupole ion trap (QIT), orbitraps, and fourier-transform ion cyclotron 
resonance (FT-ICR) [34]. Analyzer selection is decided by the necessary sensitivity, 
resolution, mass accuracy, and mass range to encompass specifications required for the 
target analysis. 
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In mass spectrometry, sensitivity refers to the ratio of the maximum number of ions 
recorded at a given m/z (of M) to the signal of the background at an adjacent m/z (of M + 
1) [35]. It takes into account the relationship between maximum useable signals acquired, 
versus the minimum useable signal (detection limit). Although detection sensitivity of the 
mass analyzer can provide a relative indicator of the maximum discernable concentrations 
of analyte within a sample, detection of low abundance components within a sample is also 
dependent on other factors such as the instrument’s resolving power. A mass spectrometer’s 
resolving power is the ability of the mass analyzer to effectively separate, define, and 
generate two distinct signals from components within a mixture with minor differences in 
m/z. Simply put, the narrower the peak, the higher the resolution. The resolution (R) for a 
single peak can be measured with,  
 
𝑅 =
𝑀
∆𝑀
 
 
(Eq. 1.1) 
 
 
Where M as the peak position (m/z), and ΔM is the width of the peak at the position of 50% 
peak height [36]. Resolving power becomes increasingly important when performing 
untargeted analysis, and when characterizing molecules with near identical masses. Mass 
accuracy in MS refers to the error in mass measurement. It evaluates the difference between 
measured, and actual m/z values of the target analyte. This measurement is usually provided 
in parts per million (ppm), and is calculated by dividing the difference of observed and true 
m/z values, by the true m/z of the analyte. The mass accuracy of a analyzer is directly 
correlated with its resolving power. Therefore, the higher the mass resolution, the greater 
33 
 
the mass accuracy.  The mass range refers to the range of m/z for which the analyzer can 
detect ions with sufficient resolution to differentiate between adjacent peaks. For many 
analyzers, increasing the mass range results in compromise with the signal detection of 
lower m/z ions, therefore the upper limit is a relative maximum, at which point the 
instrument performance becomes severely compromised.  
Different analyzers possess different mass range capabilities, and this is often the limiting 
factor when deciding upon a suitable instrument for analysis. For quadrupole mass 
analyzers, m/z selection is achieved through variations in the magnitude of radio frequency 
(RF), and the direct current (DC) applied to the four electrode rods [37-38]. The application 
of RF and DC determines the trajectory of the ions passing through, allowing for ion mass 
selection or identification. Ions with unstable trajectories are eventually neutralized 
through collision with the quadrupole electrode rods. These analyzers provide good 
reproducibility, but is limited with the resolution obtained. In conjunction with an ion trap, 
QIT mass analyzers possess a similar mechanism for m/z selection, however instead of the 
stable ion being selected, mass selection for QIT is achieved through ion instability [35, 
39]. In QIT mass analyzers, a three dimensional electric field is applied, which effectively 
traps the ions. As the RF increases, ions with higher m/z are ejected. The manipulation of 
DC and RF voltages allow for extensive MS/MS analysis of high resolution and sensitivity. 
Orbitraps contains a spindle-like inner electrode and a barrel-like outer electrode. As the 
voltage applied increases, ions are introduced into the trap. The ions oscillate along the 
horizontal axis of the inner electrode and m/z selection is achieved as ions of differing m/z 
reach the desired orbit within the trap. FT-ICR analyzers operate based on the same 
mechanism as QIT by storing ions and selecting m/z through manipulation of voltages 
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applied [39]. However, the ions travel in a circular path within a magnetic field. The ion 
mass can then be determined by detection of the cyclotron frequency for the ion’s circular 
motion. Among the available mass analyzers, FT-ICR provides the highest level of mass 
resolution, but possesses a limited mass range. For TOF mass analyzers, the ion mass is 
determined by measuring the amount of time it takes to travel through a flight tube. TOF 
mass analyzers are extremely fast, and provide a high mass range. Therefore, TOF mass 
anayzers are very desirable for targeted and untargeted protein analysis.  
 
1.3.1.1 Principles of Time-Of-Flight Mass Analyzers 
Decades after J. J. Thomson constructed the first spectrometer, time-of-flight (TOF) mass 
analyzers were introduced [33, 40]. TOF mass analyzers were conceptualized in 1946, 
however the first commercial TOF analyzer was not introduced until the 1950s. The mass 
analyzer promoted was based on designs by William Wiley, and I. H. McLaren. At this 
time, the attainable resolution was so poor that the technique was not viable for MS 
applications. Improvements in the resolution of TOF analyzers wasn’t possible until the 
development of reflectron by Boris Mamyrin. From then on, TOF analyzers continued to 
improve in resolution, and developed into an indispensible tool for mass spectrometry. 
TOF analyzers separate ions based on their mass, and measures the mass-dependent time 
required for the ions to travel through the drift tube to the detector. To start, ions generated 
in the “plume” are released from the source in sets, these ions with mass, m, and a charge 
of q = ze, are collected in an acceleration region until max capacity is reached [34, 41]. 
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Once full, a difference of potential applied between the sample plate and an extraction grid 
accelerates the ions towards the drift tube. Since the kinetic energy acquired by each ion is 
equal, separation of the ions result solely from the ion mass. High mass ions will possess a 
lower velocity in comparison to smaller mass ions. The ion velocity is then recorded based 
on the amount of time it takes for the ions to reach the detector. With the known length of 
the flight tube, and the measured ion velocity, mass-to-charge can then be calculated with 
the equation, 
 
𝑧𝑒𝑉 =
1
2
𝑚𝑣2 
         
 
(Eq. 1.2) 
 
 
𝑣 =  √
2𝑧𝑒𝑉
𝑚
 
 
         
(Eq. 1. 3) 
 
 
𝑚
𝑧
= 𝑡2(
2𝑒𝑣
𝐿2
) 
 
(Eq. 1. 4) 
 
Here, m/z represents the mass-to-charge ratio of ions, t and v represent the time required 
for ions to reach the detector, and the velocity of the ions respectively [34]. Lastly, L is the 
length of the flight tube in which the ions travel through. From the equations above, ions 
with different m/z values will travel at different velocities, and therefore reach the detector 
at different times (Eq. 1. 4). With velocity in consideration, the ions can either be positively, 
or negatively charged depending on the voltage polarity used.  
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The mode of analysis outlined above directly measures the amount of time required for 
ions to travel through the flight tube and reach the detector. With TOF mass analyzers, this 
mode is categorized as the linear mode of analysis. However, when ions are formed in the 
desorption plume, differences in initial kinetic energies exist. These differences result in a 
corresponding shift of arrival times at the detector for ions of the same mass which 
contributes to a decrease in mass resolution. In order to compensate for these shifts, a 
delayed extraction (DE) technique can be applied [42]. This delay permits the ions 
generated within the plume to expand into a field-free region in the source. The electric 
field applied remains consistent between the sample plate and the extraction grid. As a 
result, ions with higher initial kinetic energy will move further away from the sample plate 
in comparison to those with lower kinetic energies. After the delay, the ions are accelerated 
through the flight tube, where the high energy ions will experience less of a potential 
difference than the low energy ions. This allows ions of the same mass to eventually reach 
identical velocities as they travel towards the detector. Alternatively, the reflectron mode 
can be used to reduce effects of variations among initial energy distribution for ions 
generated. In reflectron mode, a series of parallel mirrors with a voltage gradient are used 
to slow, and turn ions onto a second flight path towards the detector [36]. This allows ions 
with greater kinetic energy to penetrate deeper and travel a further distance prior to 
redirecting towards the detector (Figure 1.1). As a result, ions of the same mass with 
varying initial kinetic energy will arrive at the detector simultaneously, hence improving 
the mass resolution obtained.  
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Figure 1.1  Schematics for both linear (A) and reflectron (B) modes of MALDI TOF mass 
analyzers. 
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1.3.1.2 Applications of TOF Analyzer 
TOF analyzers are now one of the most commonly used mass analyzers for MALDI MS. 
In theory, TOF possesses an unlimited mass range since ion trapping is not applied, and 
linear flight paths are used. However, in practice the detector restricts detection efficiencies 
to within a few hundred kDa mass range. Even with the confines of the detector, TOF 
analyzers provide a high practical mass range in comparison to other available mass 
analyzers [36]. TOF also has high levels of detection sensitivity, and remains the fastest 
MS analyzer available. This analyzer possesses good levels of mass accuracy, and its 
construction is comparatively inexpensive to other analyzers.  
The high mass range TOF analyzers are capable of, in conjunction with the high signal 
resolution, sensitivity, and mass accuracy, these analyzers provide the ideal parameters for 
protein analysis. When used in MALDI MS systems, the soft ionization method provides 
data regarding the molecular mass of polypeptides, while the MS/MS capabilities offer an 
additional dimension of analysis. Upon selection of a precursor ion, the amino acid 
sequence, and post translational modifications of protein samples can be identified. 
However, advantages of TOF analyzers are strongly limited by the capabilities of the 
detector employed. 
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1.3.1.3 Detectors 
All mass spectrometers aside from orbitraps and fourier-transform ion cyclotron resonance 
(analyzer acts as a detector as well) requires a detector [43]. The detectors record the ion 
intensities of each m/z value, and records the data electronically in the form of a mass 
spectrum [44]. Depending on the type of detector used, the resulting signals are produced 
by either generating secondary electrons, which are then further amplified, or by inducing 
a current using a moving charge [36]. Commonly used detectors for MS include, Faraday 
cup, electron multiplier (EM), and photomultiplier (or scintillation counter). The role of 
the detector is to be able to identify the abundance of ions present per m/z. The information 
obtained is then converted for computer based data storage, and processing in order to 
convey the data in the form of a spectra [45]. With continued development in the realm of 
ionization and separation for MS analysis, the demand for advancements in detection 
technology has become more critical. Although improvements in existing detection 
capabilities have been observed, these changes have been minimal in comparison to the 
developments made in the technology for mass analyzers. Ideally, MS detectors need to be 
consistent with ion-detection efficiency, possess minimal to no noise, capable of 
simultaneous detection of multiple ions, possesses a wide mass and dynamic range, short 
recovery time, and a high saturation level [44]. Ion detection efficiency, and level of noise 
present for detectors are limiting factors in obtaining high mass accuracy and sensitivity in 
MS measurements. The level of noise present can be a result of multiple sources, noise can 
be generated within the detector itself, or from supporting electronic sources. Techniques 
capable of minimizing effects of noise are, signal filtering, and time averaging. Although, 
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no single detector stands superior in all characteristics, choice of detector employed is 
determined by the needs of the analyzer. Detector selection for TOF mass analyzers 
prioritize a broad mass range, mass accuracy, minimal recovery time, and capabilities of 
simultaneous ion detection. Due to rapid operations of TOF mass analyzers, detectors used 
must be capable of simultaneous detection of multiple ions, and a short recovery time.  
 
1.3.2 Soft Ionization Methods 
1.3.2.1 Electrospray Ionization (ESI) 
In response to the rising demand of biological applications for mass spectrometry, “soft” 
ionization methods were developed. Electrospray ionization (ESI) was first conceptualized 
in the 1960s by Malcolm Dole, but it wasn’t until 20 years later that ESI was first applied 
for biomolecule analysis by John Fenn [33]. In ESI, there are three major steps in order to 
generate gas-phase ions, solvent introduction, solvent evaporation, and finally 
development of charged gaseous ions [46]. ESI is an atmospheric technique where sample 
solutions flow continuously (nL / min to µL/min) through a metal capillary needle held at 
an electric potential [46-50]. As an electric field is imposed on to the liquid sample, an 
enrichment of like charged ions occur near the cone. This potential difference between the 
capillary and the surrounding environment causes a dispersion of charged sample droplets 
in the form of a fine mist. The droplets then travel downfield towards the opposing 
electrode. During this process, exposure to the inert gas in the environment promotes 
solvent evaporation. As the solvent evaporates, the growing charge density results in an 
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increase in repulsion between the charges. The buildup of repulsion is eventually enough 
to overcome surface tension of the droplet, and coulomb fission occurs. This process 
continues with the parent droplets leading to secondary fissions, which eventually 
generates charged gas-phase ions. These ions are then introduced into the mass analyzer 
for separation and detection. 
ESI generally produces multiply charged ions, therefore it is able to enhance the 
capabilities of mass spectrometers with limited mass range to be applicable in the analysis 
of larger analytes. However, in order for successful detection of larger molecules, the 
instrument must possess high resolving powers to differentiate between peaks of multiply 
charged ions. ESI MS has minimal tolerance for contaminants such as salts or detergents 
which can cause adduct formation with proteins or compete with target analytes for 
ionization [46]. Therefore, ESI MS is typically coupled with on-line liquid chromatography 
(LC) to separate components within a complex mixture prior to MS analysis.  
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Figure 1.2  Illustration of an ESI ion source in positive mode. An electric field is imposed 
on the sample liquid, resulting in a build-up of positive ions near the cone. The potential 
difference between the capillary and the environment results in a dispersion of positively 
charged sample liquid in the form of a mist. As the solvent evaporates, the charge repulsion 
within each droplet builds up and eventually causes coulomb fission to occur. 
  
43 
 
 
1.3.2.2 Matrix-Assisted Laser Desorption/Ionization (MALDI) 
Matrix-assisted laser desorption/ionization (MALDI) was first introduced by Franz 
Hillenkamp and Michael Karas in 1988 [36]. Over the past 30 years, MALDI has 
developed into a technique that is applicable to various scientific fields, including 
chemistry, biochemistry, biology, and even in clinical settings. While ESI converts liquid 
phase analytes to gas phase ions for analysis, MALDI converts solid phase analytes to gas 
ions. This technique generates primarily singly charged molecules, and has a higher 
tolerance against contaminants in comparison to ESI. This makes MALDI MS a valuable 
tool for untargeted research of complex biological systems.  
In the MALDI MS process, analyte molecules are embedded in the crystalline structure of 
a small organic compound called the matrix. This mixture is then deposited onto a MALDI 
target plate. Once dried, the sample is introduced into the mass spectrometer, where the 
sample-matrix mixture is irradiated by a UV laser pulse (typically of wavelengths 337 nm 
and 355 nm). The laser causes heat production at the target plate, resulting in localized 
sublimation and ultimately ionization of the sample-matrix mixture releasing the molecules 
into the gas phase [51]. Both ions and neutral molecules are generated from this process, 
but only the ions are accelerated by the electric field towards the analyzer for separation 
followed by detection.  
MALDI matrix selection is extremely important in order for successful detection of target 
analytes. Although guidelines are available for the most common matrices, definitive 
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selection of a suitable matrix is still a process of trial-and-error as a result of the 
uncertainties with the mechanism of the ionization process. Ionization of target samples 
with MALDI is a two part process, first the matrix must be ionized, and this is followed by 
an ion-molecule reaction to generate charged analyte ions [36, 52-53]. Several models have 
been proposed in attempts to elucidate the phenomenon, but it is highly unlikely to generate 
a model that can encompass the range of parameters that may affect the ionization 
environment. Among the proposed mechanisms, the most widely accepted hypothesis 
involves a gas-phase transfer of protons from matrix to analyte. In this model, matrix ions 
are generated in the primary ion formation, resulting in an expanding matrix “plume”. A 
secondary ionization then occurs as a proton transfer takes place between the matrix and 
analyte thereby desorbing and ionizing the analyte molecules [54]. 
Since its conception, MALDI MS has become a well established technique in the analysis 
of a wide range of samples, including proteins, peptides, oligonucleotides, polysaccharides, 
lipids, synthetic polymers, and inorganics. Among its applications, MALDI MS has been 
most prominent in the analysis of peptides and proteins since they have a much higher 
proton affinity (10-3 – 10-4) in comparison to analytes like carbohydrates (10-7 – 108) [55-
59].  
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1.4 Application of MALDI Mass Spectrometry  
1.4.1 Role of MALDI Matrices 
Overall, there is a general consensus in the significance of MALDI matrices in the entire 
ionization process, however controversy exists in the ionization mechanism. A suitable 
mechanism should be able to explain the presence and abundance of all the ions generated, 
but so far none of the proposed mechanisms are capable. It is also extremely difficult to 
generate one hypothesis which can encompass the range of experimental and instrumental 
conditions which may affect the ionization of the matrix-analyte mixture. The controversy 
primarily surrounds the initial ionization of the matrix molecule. However, there are higher 
levels of acceptance regarding the proposed mechanism in which secondary ionization 
generates charged analyte ions. During this secondary ionization process, proton transfer 
occurs between the matrix and the analyte [51, 53]. The matrix acts as both a proton donor 
and acceptor facilitating the generation of ions in both positive and negative modes, 
respectively. During this process, energy resulting from this transfer is also received by the 
analyte. The level of energy that is transferred directly influences the degree of in source 
fragmentation that occurs [60]. Different matrices transfer different degrees of energy 
during this process, matrices that provide a greater energy transfer are considered “hot” 
matrices, while lesser energy transfer indicates the matrix is “cold” [42]. The matrix also 
plays a protective role in shielding the analyte from the initial laser irradiation, and 
therefore minimizes undesirable fragmentation making MALDI a “soft” method of 
ionization.   
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1.4.2 MALDI Matrices and Deposition Methods 
Several criteria must be met for MALDI matrices to effectively ionize the target samples. 
Most commonly used matrices are solid, organic acids. However, continuous investigation 
into effective, novel materials have shown success in use of liquid matrices, and solid 
micro/nano particles. Matrices must also be readily soluble in commonly used sample 
preparatory solvents (eg. acetonitrile, ethanol, methanol etc.), relatively stable in a vacuum 
environment, provide a homogenous matrix-analyte deposit, and possesses strong UV 
absorbing capabilities at the laser wavelength.  
The three most commonly used matrices are, 2, 5-dihydroxybenzoic acid (DHB), α-cyano-
4-hydroxycinnamic acid (CHCA), and sinapinic acid (SA). The latter two are 
predominantly used for peptide and protein analysis respectively [61]. The structures of 
each have been shown in Figure 1.3. DHB has a molecular weight of 154.12 g/mol, and it 
is capable of absorbing UV wavelengths of 266 nm, 337 nm, and 355 nm. Among the three 
standard matrices, DHB produces less background signals from matrix clusters. Therefore, 
this matrix is suitable for analysis of the lower m/z range, where signals from matrix 
clusters are often observed. DHB is considered a “cold” matrix, therefore minimal loss of 
neutral groups attached to the protein backbone during the ionization process occurs [62]. 
As a result, DHB is commonly used for the study of proteins with post translational 
modifications (PTMs), phosphopeptides, and glycoproteins.  
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Figure 1.3  The structure of three commonly used matrices in MALDI MS have been 
shown. All three matrices are small, organic acids consisting of an aromatic ring. Each 
matrix possesses UV absorbing capabilities in the 337 nm, and 355 nm wavelengths. 
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CHCA has a molecular weight of 188.16 g/mol, and it is widely used to facilitate ionization 
of peptides or small proteins with a molecular mass of < 10,000 Da. CHCA matrix 
generates a homogenous matrix-analyte deposition, which contributes to a high shot-to-
shot reproducibility making it very effective in peptide mass fingerprinting. This matrix 
absorbs UV at both 337 nm and 355 nm wavelengths, and is readily soluble in polar 
solvents. Successful application of CHCA has also been reported for lipid and nucleotide 
analysis, but it is important to note that this matrix generates numerous peaks within the 
100 - 400 m/z region . CHCA is also effective in the detection of low concentration protein 
digests using MALDI-TOF MS.  
SA has a molecular weight of 224.21 g/mol, and is mostly used in the positive mode of 
analysis. Like DHB, it is considered a “cold” matrix, and capable of absorbing UV 
wavelengths of 266 nm, 337 nm, and 355 nm. SA can be applied to peptide analysis, but 
generally it excels in the detection of intact proteins because of the lesser degree of in-
source fragmentation observed [63]. Continuous development of potential MALDI 
matrices have generate several alternative compounds which have shown to be effective in 
facilitating ionization in MALDI MS. These compounds, dihydroxyacetone phosphate 
(DHAP), 1, 5 – diaminonaphthalene (DAN), 2, 4, 6 – trihydroxyacetophenone (THAP), 
and 2 – (4 – hydroxyphenylazo)benzoic acid (HABA) along with the primary analytes they 
target have been listed in Table 1.2. 
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Table 1.2  Alternative matrices developed for MALDI MS analysis, and the target analyte 
of interest each matrix is most successfully used for have been listed. Unfortunately, as a 
result of the uncertainties with the ionization mechanism, these are all simply guidelines 
when choosing a matrices for experiments. The guidelines help to narrow down the 
selection, however trial-and-error is required to determine the optimal selection for the 
target analyte. 
 
 DHAP DAN THAP HABA 
Glycoproteins   X X 
Complex Protein Profiling X    
Gangliosides  X   
Oligonucleotides   X  
Glycolipids    X 
Synthetic Polymers    X 
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Sample preparation methods are another factor that greatly effects signal detection. 
Standard MALDI MS samples utilize the dried-droplet method that was first introduced by 
Hillenkamp and Karas. To facilitate co-crystallization, matrix and samples solutions are 
first premixed in a 1:1 ratio. This mixture is then spotted (0.5 µL – 1 µL) onto a MALDI 
target plate. Once dried, the sample plate can be inserted into the vacuum system for 
analysis. Alternatively, two-layer, three-layer, and sandwich deposition methods are also 
available. Many variations of the first two layered techniques exists. Generally, it involves 
spotting the matrix, analyte, or matrix-analyte mixture in succession. Sandwich methods 
normally involve the sample solution to be “sandwiched” between two layers of matrix 
deposits. Overall, matrix molecules must be present in excess for efficient ionization to 
occur.  
 
1.5 Introduction of MALDI Mass Spectrometry Imaging 
(MALDI MSI) 
1.5.1 Theory of MALDI MSI 
1.5.1.1 Ionization of Analytes from Intact Tissue Sections 
Three ionization techniques used in MSI analysis of intact tissue samples are secondary 
ion mass spectrometry (SIMS), desorption electrospray ionization (DESI), and MALDI. 
SIMS utilizes an ion beam directed at the sample surface in order to induce the release of 
secondary analyte ions for analysis. Although this technique provides images of the 
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greatest spatial resolution, it is a hard ionization method and therefore mostly used for 
analytes in the lower mass range (<1000 Da) [64]. Alternatively, DESI was introduced by 
Dr. Graham Cooks’ research group as a soft ionization method capable of applications 
within atmospheric conditions [65]. DESI was developed based on the principles of ESI 
and desorption ionization techniques. Ionization occurs as charged droplets are directly 
applied onto the sample surface. The charged droplets coat the sample allowing for analyte 
extraction. Continuous spray application results in momentum transfer from droplet 
collisions and subsequently desorbs analyte ions from the sample surface towards the mass 
spectrometer. Development of DESI provides an ionization technique for MSI analysis of 
small molecules, lipids, and peptides (< 2000 Da) [66-67]. 
Development of MALDI MSI by Dr. Richard Caprioli’s research group provided an 
alternative soft ionization method for MSI analysis. The molecular specificity and wide 
mass range of MALDI-TOF MS has made this technique a powerful tool for imaging intact 
biological samples [68-69]. In comparison to the aforementioned ionization methods for 
MSI, MALDI provides the greatest applicable mass range making this technique most 
suitable for simultaneous MSI analysis of proteins and peptides. MALDI MSI uses fixed 
UV laser pulses to extract analyte information from matrix coated tissue sections. This 
method of analysis is non-destructive, the ionization process ablates only the matrix layer, 
leaving the underlying tissue intact for alternative forms of analysis post imaging. Due to 
the complexity of the tissue surface, matrix selection becomes increasingly important to 
facilitate the ionization of desired components within the tissue section, while minimizing 
undesirable signal detection from the tissue background or matrix. Parameters such as m/z 
range, rastor size, laser intensity, shots/ spot, and region of interest (ROI) must be optimized 
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for each sample. Once determined, laser pulses ablate each spot as it travels throughout the 
designated ROI. These ablations generate analyte ions per spot. The data is then collected, 
and processed to represent each pixel within an image of the ROI. A general schematic has 
been provided in Figure 1.4.  
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Figure 1.4  A schematic of the MALDI MSI workflow. Once the MALDI MSI paramters 
are selected, the laser moves along the ROI ablating spot after spot. Information is then 
collected for the molecules present within each ablated spot. This information can then be 
collectively used to generate a tissue image. 
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1.5.1.2 Signal Detection Sensitivity versus Image Spatial Resolution 
In MALDI-TOF MSI analysis, both sensitivity and spatial resolution contribute 
significantly to the quality of the image generated. Detection sensitivity measures the 
instrument’s ability to detect the lowest abundance analyte within a sample, while spatial 
resolution describes the ability to resolve two peaks of similar m/z values [70]. The 
measurement of sensitivity is directly related to the detection limit of the technique, in 
presence of comparable S/N, the greater the detection sensitivity the lower the detection 
limit. Therefore, when analyzing proteins and peptides, high levels of sensitivity are 
desired in order to overcome issues of lipid abundance within tissue sections. However, the 
degree of detection sensitivity acquired is inversely correlated with the level of resolution 
attained. The ability to clearly identify two components of a mixture with similar m/z is 
extremely beneficial, especially when analyzing biological samples. 
To improve detection sensitivity, a larger number of ions must be sent to the detector in a 
shorter time frame. This helps to enhance the signal-to-noise (S/N) ratio, and increase the 
number of ions detected [36]. Although this may aid to improve sensitivity of detection, 
increasing the volume of space for which ions may travel through to the detector, 
negatively impacts the resolving power of the instrument. In order to improve the resolving 
capabilities, the spatial distribution of the ions must be accounted for. A greater volume of 
space contains more ions, but ions of the same m/z with variations in starting energy and 
spatial distribution will contribute to differences in arrival times. This in turn decreases 
resolution attained. In extreme cases where parameters are greatly optimized for sensitivity, 
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the extremely low resolving capabilities will lead to a decrease in S/N as well. Therefore, 
in all experiments, a compromise must be made between sensitivity and resolution in order 
to find the optimal ratio to provide the necessary information that will answer the question 
at hand.  
 
1.5.2 Applications of MALDI MSI 
1.5.2.1 Tissue Collection and Storage 
Appropriate tissue handling and treatment techniques are crucial in obtaining successful 
MALDI MSI results. This involves identifying suitable tissue extraction, sectioning, and 
sample preparation techniques. These techniques will differ depending on the sample, and 
question under analysis. Therefore, an evaluation is required prior to analysis of every new 
sample. Two tissue collection techniques are available for MALDI MSI, fresh frozen and 
formalin-fixed paraffin embedded (FFPE) tissue.  
With fresh frozen tissue, the greatest issue resides in the ability to homogenously freeze 
the tissue section immediately after extraction to maintain integrity and shape. Immediate 
freezing helps to minimize protein degradation, which occurs immediately post-mortem 
through enzymatic proteolysis. Homogenous freezing can be accomplished through use of 
liquid nitrogen, or dry ice. A homogenous freeze minimizes development of ice crystals 
within the tissue section, these crystals can then increase chances of tissue fractures upon 
sectioning [71]. The tissue can be lightly wrapped with aluminum foil prior to submersion 
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in liquid nitrogen, or buried in dry ice to promote a “gentle” freeze application. This can 
help to prevent tissue deformities, and the formation of fractures during the freezing 
process. Once retrieved, the tissue needs to be stored in – 80 oC to minimize degradation 
and chances of ice crystal formation. 
Alternatively, recent developments in MALDI MSI allow for the analysis of FFPE tissue. 
When tissues are treated with formalin, inter- and intra-molecular crosslinking occurs 
between primary amino or thiol groups and arginine, cysteine, tryptophan, lysine, and 
histidine residues [72-73]. This crosslinking provides stability and helps to preserves tissue 
structure. Therefore, FFPE samples are commonly collected in batches to develop tissue 
banks since FFPE tissue can remain stable for decades at room temperature [74]. Although 
tissue integrity can be preserved with this method, when analyzing proteins, paraffin is not 
compatible with MALDI MSI. Presence of paraffin can result in significant ion suppression 
effects, therefore removal must be accomplished through xylene washes prior to analysis 
[75]. In addition to paraffin removal, on-tissue digestion is often used to help facilitate 
protein and peptide identification among crosslinked proteins [76]. This process helps to 
preserve the spatial distribution of resulting peptides for identification. 
FFPE tissue retrieval method provides a sample of high stability in comparison to fresh 
frozen tissue. However, sample preparatory steps required for successful MALDI MSI 
analysis of FFPE tissue is extremely extensive. The paraffin removal process may not 
always be 100% successful resulting in ion suppression of lower abundance analytes. 
Additionally, the ability to simultaneously detect multiple analytes within tissue samples is 
hindered as a result of degradation of lipids within FFPE tissue sections since the only 
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molecules preserved are the crosslinked proteins [76]. Therefore, fresh frozen tissue is 
often selected in order to preserve the native distribution of analytes within tissue sections, 
and to be able to study multiple analytes per sample acquired.  
 
1.5.2.2 Tissue Sectioning and Mounting 
Selection of tissue sectioning methods is dependent on the extraction technique used. For 
fresh frozen tissue, the tissues are secured onto the holder using water which is flash frozen 
with dry ice. As the tissue samples are secured onto the holder, it is important to minimize 
embedment of the sample area in water. Embedding the sample in water can result in a 
decrease in signal detected as a result of ion suppression effects [77]. Once secured, the 
holder can then be placed into the cryotome set to a temperature of -20 to - 25 oC for 
sectioning. If the temperature is set too low, chances of tears and tissue fractures occur, but 
if the temperature is too high, tissue deformation may occur. Variations in temperature 
exists between runs resulting from changes in the temperature and humidity of the 
environment. Therefore, if sectioning is performed in an unregulated environment, 
temperature settings must be adjusted accordingly. The degree of blade sharpness also 
plays a critical role in the quality of sample sections obtained. Ideally, a fresh blade is used 
per sample run to minimize variables that could contribute to lack of reproducibility. Tissue 
thickness varies between 10 – 35 µm [69]. The optimal tissue thickness is inversely 
correlated with the molecular weight of the target analyte in order to facilitate extraction 
of larger analytes from the tissue section.  
58 
 
Once sectioned, tissue is mounted onto indium tin oxide (ITO) coated glass slides. Two 
mounting methods are available, flip mounting and thaw mounting. Flip mounting is when 
the ITO glass slide is pressed on top the sectioned tissue sample, therefore resulting in the 
tissue inversely mounted onto the slide. This mounting method reduces chances of tissue 
tearing and deformation, but an increase in noise is detected for these samples. Therefore, 
if low abundance analytes are in question, this technique would not be favorable. 
Alternatively, the thaw mounting method generates data with a cleaner baseline. Thaw 
mounting requires the use of thin brushes to maneuver the tissue section onto the glass 
slide. Once desired placement is obtained, the tissue can be thawed onto the ITO glass slide 
by placing a finger underneath the slide. Once mounted, the tissue sections must be treated 
and analyzed immediately.  
For FFPE tissue, sectioning is accomplished using a microtome at room temperature. As 
the tissue is sectioned, it is transferred to a water bath of 37 oC, and mounted onto an ITO 
coated glass slide. In order to ensure tissue adhesion to the glass surface, presence of water 
must be completely removed. This can be accomplished through incubation of the slide at 
30 – 37 oC for 1 - 2 minutes. Once mounted, the tissue can be stored at room temperature 
for several months prior to analysis.  
 
1.5.2.3 Matrix Application Methodology 
MALDI MSI requires the presence of a UV absorbing matrix to be coated on top of the 
tissue sections in order to help facilitate the soft ionization process. The matrix deposited 
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plays a vital role in the quality of images obtained. Crucial parameters that require 
optimization are, uniformity, concentration, and matrix selection. Uniformity of the matrix 
layer along the entire tissue section is extremely important for consistent signal detection 
in order to obtain an accurate spatial comparison of analytes across the entire ROI. If 
uneven application occurs, the concentration of matrix will vary among different areas of 
the tissue resulting in differences in the signal intensity detected. Concentration of matrix 
used is also extremely important, there is a set window for the optimal matrix concentration 
per sample analyzed. If the concentration falls below this range, the analyte to matrix ratio 
will be insufficient to maximize signal detection, but if the concentration is greater than 
this range, the matrix will act to suppress desired analyte signals. Therefore, optimization 
of the matrix concentration is required per sample analyzed. Matrix compatibility with 
target analytes must also be considered. Not only does the matrix selection have to be 
suitable to the type of analyte under investigation, the solvents used to solubilize the matrix 
must also be compatible with the sample. Three methods of matrix application are 
available, airbrush, automated sprayer, and sublimation.  
Airbrush application is a fast and simple method for matrix deposition for MALDI MSI. 
The matrix selected is dissolved in the appropriate solvent and sprayed using an artisan 
airbrush onto the tissue section. A major disadvantage of this technique is its poor 
reproducibility. Huge variations exist between users since the velocity, duration, and 
direction of the spray is controlled manually. Therefore, the quality of the spray can vary 
not only between users, but between runs. Although the presence of a solvent facilitates 
analyte – matrix interactions which increases extraction potential, a significant concern 
60 
 
resides in the possibility of spraying too much solvent resulting in delocalization of 
analytes on the tissue surface.  
Development of automated sprayer systems such as the TM – Sprayer from HTX 
Technologies, helped to remove variability in spray parameter. This improved the 
reproducibility between runs, and minimized user-to-user variations when depositing 
matrix. Automated sprayers provided a platform for users to have full control over desired 
spray parameters such as velocity, flow rate, number of passes, spray temperature, and 
spray pattern. The robotically controlled nozzle then applies the matrix using the preset 
parameters, which allows for the density of matrix applied to be calculated. The ability to 
control flow rate helped to facilitate the degree of analyte extraction without significantly 
compromising spatial resolution of images acquired. The capabilities of automated 
sprayers in regulating parameters to optimize for extraction potential, makes this method 
ideal when studying low abundance analytes such as, proteins and peptides.  
Among the three techniques, sublimation is the only solvent free application method. With 
sublimation, the matrix is placed in the bottom of the reservoir, while the tissue mounted 
slide is taped directly above. Ice is added to the reservoir above the slide, and heat is applied 
below the matrix reservoir with the entire system under vacuum. The matrix goes directly 
from the solid state to the gaseous state. As the matrix particles rise, the ice above cools 
the region around the slide resulting in the matrix particles returning to solid state, and 
subliming onto the slide. This form of matrix application generates a uniform coating with 
a small matrix crystal size. This solvent free technique eradicates the potential of analyte 
delocalization, therefore generating images of high spatial resolution. However, the 
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absence of solvent also removes the analyte – matrix interaction period, resulting in poor 
extraction efficiency. Therefore, sublimation is ideal for generating images of high spatial 
resolution for easily extracted or high abundant analytes.  
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Figure 1.5  Sublimation was accomplished by adhering the tissue mounted ITO slide onto 
the top half of the glass apparatus. This was placed onto the container with the pre-weighed 
dry matrix, and the apparatus was then connected to the vacuum pump. Once under 
vacuum, the glass apparatus was placed on the heated sand surface. 
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1.5.2.4 Sample Rehydration Methodology 
As a final step in the sample preparation procedure prior to MALDI MSI analysis, 
rehydration is employed to help increase the opportunity for analyte – matrix interactions. 
This protocol aims to improve analyte extraction in order to increase detection capabilities. 
Rehydration is typically achieved using an acidic solvent within a closed chamber. A filter 
paper soaked in the acidic solvent is placed at the base of the chamber, while the tissue 
mounted slide is taped onto a metal heat sink attached to the top of the chamber directly 
above the solvent. This chamber is sealed and placed in 70 – 85 oC incubator for 3 - 5 
minutes. Optimizations for incubation temperature and time vary depending on the matrix 
used. This step has been found to improve signal detection for all analytes under 
investigation.  
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Chapter 2: Alzheimer’s Disease and the Amyloid 
Cascade Hypothesis 
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2.1 Introduction to Alzheimer’s Disease  
Alzheimer’s diseases (AD) is a progressive, and currently irreversible neurodegenerative 
disease which affects more than 80% of dementia cases worldwide [1]. This disease can be 
categorized into two groups, early-onset AD and late-onset AD. Early–onset is regarded as 
the manifestation of AD symptoms before the age of 60. This familial form of AD is caused 
by the inheritance of mutated amyloid precursor proteins (APP), and/or presenilin proteins 
which represents approximately 1-6% of all AD occurrences [2-5]. Alternatively, numerous 
hypotheses for causation factors have been proposed for late-onset AD. However, the 
multi-faceted nature of the disease makes it difficult for one theory to encompass all of the 
contributing factors for disease development. Biologically, neuronal damage resulting from 
AD pathology occur decades prior to the onset of cognitive and behavioural symptoms [6-
8]. During the preclinical stages of the disease, development of amyloid beta (Aß) 
oligomers, plaques and tau tangles in the brain continue to facilitate neuronal damage 
through disruption of connections eventually resulting in neuronal death [9]. This damage 
appears to occur initially in the hippocampus, as a results, the first clinical symptoms 
observed tend to be the loss of one’s memory [10-12]. As the disease continues to progress, 
the damage eventually spreads throughout the brain, and the symptoms of AD get 
progressively worse as it impairs mental, behavioral and functional capabilities of those 
affected.  
Manifestation of symptoms result in tremendous emotional and financial strains to both the 
patient’s families and the health care system. With the incidence rate of AD estimated to 
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affect over 1 million Canadians by 2038, AD research has become a prevalent field of study 
[13]. Extensive studies in the pathology of AD resulted in constantly changing theories of 
causation. Initially, disease manifestation was characterized by high levels of amyloid 
plaques, and therefore emphasis was initially placed studying plaque characterization and 
development. However, eventually the hypotheses of causation factors shifted to tau 
phosphorylation and the Aß peptides as the primary culprits [8]. Challenges in elucidating 
AD pathology has resulted as a hindrance to the development of diagnostics and treatments 
for the disease. As a result, increased interest has resided in the ability to develop and 
explore alternative techniques for the analysis and detection of Aß proteins in hopes to 
provide clarity regarding the complex web of factors that contribute to the development of 
AD. 
 
2.1.1 Alzheimer’s Disease Pathology 
Genetic, environment, behavioural and developmental components all influence the onset 
and progression of AD. Therefore, the ability to elucidate definitive cause and effect factors 
for this multifactorial disease have been challenging [1]. The earliest hypothesis described 
two hallmarks of AD, the accumulation of amyloid resulting in amyloid plaques, and 
abnormal hyperphosphorylation of tau leading to neurofibrillary tangles (NFTs) [14-15]. 
This hypothesis relied on the premise that Aß accumulated in extracellular space resulting 
in the development of senile plaques. These plaques then, in turn, led to the formation of 
NFTs which both contribute to cell loss, and eventually dementia [16]. However, 
continuous research revealed the lack of correlation between disease manifestation and the 
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degree of plaque development observed. Additionally, not only was neuronal damage 
detected in brain regions free from plaques, significant amyloid plaque formation was 
discovered in cognitively normal individuals as well [17-20]. Furthermore, the formation 
of amyloid plaques does not occur until much later in AD development, and is therefore 
unlikely to be the main driving force of disease progression [21]. Consequently, multiple 
theories and factors were hypothesized based on different causation factors of AD as 
presented in Figure 2.1. These hypotheses include: the tau hypothesis, inflammation 
hypothesis and the amyloid cascade hypothesis (ACH) [22]. Each hypothesis encompasses 
multiple factors that cause the onset of AD symptoms. The tau hypothesis postulates that 
abnormal increases in hyperphosphorylated tau proteins found in AD patients result in the 
loss of normal tau functions leading to neuronal dysfunction [23-27]. The inflammation 
hypothesis focuses upon the inflammation of the central nervous system which leads to 
oxidative stress followed by neuronal death [28-29]. The ACH indicates that Aß 
accumulation is the primary initiator that triggers a cascade of events resulting in neuronal 
death and dementia exhibited in AD patients [7]. 
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Figure 2.1  A simplified schematic demonstrating factors that influence AD development 
and progression modified from Anand et al. [1]. The factors are found to be largely 
interconnected in causation and effect. All the individual events lead to neuronal death or 
dysfunction, and the eventual onset of dementia. 
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2.1.2 Amyloid Cascade Hypothesis (ACH) 
Among the proposed hypotheses for AD development and progression, ACH retains focus 
due to the correlations observed regarding neuronal toxicity, and the presence of soluble 
Aß oligomers. The presence of Aß oligomers were found to induce neuronal damage, and 
induce memory loss with or without plaque formation [30-31]. In the preliminary phase of 
ACH development, researchers believed the overproduction, or a decrease in clearance 
efficiency of Aß peptides resulted in an accumulation of Aß1-40 and Aß1-42 [8]. As the 
concentration of Aß peptides increases, peptide aggregation occurs which induces a 
multifaceted neurotoxic cascade of events. This includes the hyperphosphorylation of tau 
proteins, neuronal loss, cerebrovascular damage, and microglia activation [30].  
Aß production results from proteolytic processing of the amyloid precursor protein (APP). 
This occurs either through the amyloidogenic, or non-amyloidogenic pathways. In normal 
conditions, the non-amyloidogenic pathway uses α-secretases which cleaves APP within 
the Aß domain (between Lys16 and Leu17) resulting in the release of sAPPα. However, 
under pathological conditions, the amyloidogenic pathway uses ß-secretases. The ß 
cleavages site is located at the beginning of the Aß domain, therefore lceavage through ß-
secretase generates sAPPß. The following γ-secretase cleavage then releases Aß peptides 
[8, 14, 32]. Continuous Aß production along with poor Aß removal induces the damages 
which eventually results in neuronal death. The development of the ACH throughout the 
years has made this theory the most well defined, and greatly studied concept for AD 
pathology. 
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2.2 Amyloid Beta 
2.2.1 Physical Properties 
Aß plays an important role in biological processes such as signaling, neuronal development 
and intracellular transport [33]. The amino acid sequence of these peptides contains 
approximately 50% hydrophobic residues with the majority of these residues concentrated 
on the latter half of the sequence (Figue 2.2). The hydrophobic stretches in the middle and 
C-terminus of Aß1-42 are the driving forces of the aggregation process [34]. The 
hydrophobic composition of Aß creates challenges in sample handling under research 
conditions. Therefore, strong emphasis must be placed on ensuring sample integrity prior 
to additional analysis on biological effects within an experimental system.  
 
Aß1-40 
 
DAEFRHDSGY EVHHQKLVFF AEPVGSNKGA IIGLMVGGVV 
 
Aß1-42 DAEFRHDSGY EVHHQKLVFF AEPVGSNKGA IIGLMVGGVV IA 
Figure 2.2  Amino acid sequence of pathogenic Aß peptides 1-40 and 1-42 have been 
provided. The peptide contains approximately 50% hydrophobic residues (shown in red). 
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2.2.2 Aß Assemblies 
Monomeric Aß undergo aggregation which results in the formation of low molecular 
weight oligomers followed by higher molecular weight aggregates. These aggregates 
develop into spherical oligomers comprised of 12 to 24 monomers. The spherical structure 
then elongate into protofibrils, and finally insoluble fibrils as seen in Figure 2.3 [35]. These 
variations in Aß assemblies then come together to form amyloid plaques. The soluble Aß 
oligomers possess a heterogeneous size distribution in vivo due to the monomers propensity 
for spontaneous aggregation [33]. With the help of circular dichroism (CD), infrared 
spectroscopy and hydrogen/deuterium exchange (HDX), Aß oligomers were found to 
possess significant ß-sheet secondary structures [36]. The transient nature of Aß oligomers 
make it extremely difficult to produce in vitro samples of homogenous oligomer 
composition, making the structural characteristic of Aß oligomers more challenging to 
identify [37]. The staple characteristic of these oligomers is the apparent ß-sheet structure 
arranged in parallel and antiparallel fashion [38]. Initially, development of spherical 
oligomeric aggregates was thought to be required prior to the formation of long protofibrils 
leading to the formation of fibrils. However, studies indicated protofibril development can 
potentially occur directly from the monomeric state as well. Uncertainties in Aß structure, 
and the developmental pathways elicit continuous developments in analytical methods for 
the identification and analysis of this protein.  
Unlike the dynamic oligomeric form of Aß, the static structure of the Aß fibrils has been 
well characterized. Aß1-40 and Aß1-42 fibrils consist of ß-strands which run perpendicular to 
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the fibril axis [39]. The ß-strands run antiparallel in a ß-hairpin motif, where the first and 
second ß-strands are connected by a short loop [40-43]. The first ß-strand begins after the 
initial disordered stretch of amino acid residues at the N-terminus (approximately residues 
1-14). This strand is followed by a turn which leads into the second ß-strand [44-45]. 
Hydrogen bonding between these strands results in parallel stacking of the protomers 
forming protofibrils. The protofibrils developed can then twist together to become mature, 
stable fibrils. The ß-sheet structure of amyloid fibrils act efficiently in burying the 
hydrophobic side chains within. Complete elucidation of the Aß aggregation pathway for 
the development of toxic oligomers, and stable fibrils may help to reveal underlying 
mechanisms of Aß related neurodegenerative diseases. 
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Figure 2.3  Different stages of Aß aggregation has been presented in the currently 
understood aggregation pathway. Aß monomers aggregate to form a heterogeneous 
composition of soluble oligomers. These oligomers elongate to form the transitional 
protofibril structure prior to the development of mature, insoluble fibrils. However, 
supporting evidence indicate the monomeric form of Aß can potentially aggregate directly 
into protofibril formation as well. 
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2.2.3 Biological Functions & Neurotoxicity of Amyloid Beta 
The complexity of AD resulting from the pathogenic interactions between genetics, 
epigenetics, and the environment makes it challenging to develop therapeutic interventions 
for AD management. Novel therapeutics are focused on facilitating amyloid oligomer 
reduction by inhibition of Aß production, or by improving the efficiency of Aß degradation 
through over-expression of Aß degradation enzymes [33]. Beta (ß)- and Gamma (γ)- 
secretase inhibitors, or modulators have been introduced as a means to prevent the 
production of Aß by minimizing the cleavage of APP through the amyloidogenic pathway. 
The hope was that this process would defer APP cleavage towards the non-amyloidogenic 
pathway using α-secretase [46]. Unfortunately, these interventions are still undergoing 
clinical trials, therefore there are a limited number of approved drug treatments currently 
available for AD management [33]. 
Increased understanding of the mechanisms for Aß toxicity is required to further the 
development of therapeutic treatments for AD. However, due to the complexity of oligomer 
formation, there has been several proposed mechanisms for Aß toxicity [47]. Aß toxicity 
has been linked to the disruption of receptors, including the induction of the nerve growth 
factor (NGF) receptor mediated neurodegeneration and cell death [47-49]. Aß was also 
found to bind to membrane proteins such as insulin receptors. Similarities in structure result 
in Aß competing with insulin for insulin degrading enzymes resulting in the impairment of 
glucose metabolism observed in AD [50-51]. Since the plasma membrane regulates the 
exchange of materials between cells and the environment, the structural integrity of these 
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membranes is crucial for cellular viability. xtracellular aggregation of Aß deposits within 
the hippocampus, amygdala, entorhinal cortex and basal forebrain contribute towards the 
deteriorating memory, learning and emotional behaviours found in patients suffering from 
AD [33, 59].  
In attempts to isolate therapeutic interventions, the development of various techniques for 
in vitro Aß analysis have been developed. Researchers aimed to probe the physical and 
chemical properties of these toxic proteins to identify the origins of its toxicity within 
biological systems. These techniques include: nuclear magnetic resonance (NMR), X-ray 
diffraction crystallography, as well as spectroscopy and microscopy based methods. Both 
NMR and X-ray diffraction crystallography are able to provide 3D structures of 
amyloidogenic peptides and proteins. NMR is able to monitor protein folding, including 
the secondary structures, along with the interactions among different regions of the protein 
[60-62]. Through NMR analysis, amino acid residues 1-14 were found to be unstructured, 
polar, water soluble residues while segment 15-36 form α-helical structures [63]. Helical 
sections of the protein convert to coils upon the loss of a proton for two acidic amino acid 
residues. This conversion was found to precede the aggregation of Aß1-40 [63]. In 
comparing the physical structure of Aß1-40 and Aß1-42, residues 31-34 and 38-41 in Aß1-42 
was found to form ß-hairpin structures resulting in a reduction of the flexibility at the C-
terminal [64]. This was speculated to be a factor of the peptides greater propensity for 
aggregation in comparison to Aß1-40. Currently, gel electrophoresis is commonly used for 
identification of Aß aggregation in biological samples [65]. This technique relies on the 
ability of SDS to bind to proteins of interest, however this binding can also compromise 
the structural integrity of desired aggregates [66]. Issues regarding low sample throughput, 
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limitations in resolution, as well as gel smearing can reduce the effectiveness of this 
technique. Alternatively, atomic force microscopy (AFM), surface plasmon resonance 
(SPR), absorbance, and fluorescence spectroscopy have been used to study Aß composition 
with some success [67-68]. Each technique possesses its own set of limitations. AFM is 
most suitable for studying large, stable amyloid fibrils, while SPR is generally used to 
investigate the interaction of Aß aggregates. Both absorbance and fluorescence 
spectroscopy present restrictions in the ability to differentiate between aggregates of 
differing sizes.  
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2.3 Amyloid Beta Imaging 
Techniques for Aß imaging within intact tissue sections have evolved greatly in the past 
two decades in response to the increasing demands within both research and commercial 
fields. Localization of Aß proteins within intact brain sections can help to elucidate AD 
progression and associate effects patients experience. Traditionally, histological stains 
using Congo Red or Thioflavins on formalin-fixed paraffin embedded (FFPE) tissue can 
be used for the identification of amyloid in tissue samples [69-70]. Alternatively, 
monoclonal mouse antibodies can be used to tag, and locate pre-amyloid and amyloid 
deposits with immunohistochemistry (IHC). However, issues reside with background 
staining caused by serum cross reactivity, or poor antibody specificity [71-72]. 
Through the introduction of mass spectrometry imaging (MSI), comprehensive analysis of 
the spatial distribution for molecular components eliminates the need for chemical staining, 
or antibody labelling. Over the last 10 years, continuous developments in matrix-assisted 
laser desorption/ionization mass spectrometry imaging (MALDI MSI) has been beneficial 
for the spatial profiling of amyloid plaques. However, currently MALDI MSI analysis of 
Aß has been limited to the detection of fibrillary Aß and amyloid plaques, both of which 
possess very stable, sedentary structures of considerable size [73-76]. The ability to 
identify soluble oligomeric forms of Aß through MALDI MSI is still required. Chapter 3 
aims to present MALDI MS as a method of analysis for soluble Aß oligomeric samples. 
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2.4 Overview of Thesis 
The main goal of this thesis is to improve methods for protein and peptide detection in 
MALDI MSI. A picture says a thousand words, we hope to apply this technique for the 
analysis of proteins and peptides in order to provide additional insight on disease 
development and progression. In the past few years, MALDI MSI has become a prominent 
tool in the study of intact biological samples. This method provides a new platform to not 
only identify and characterize target molecules within tissue samples, but also to 
investigate the significance of the distribution for these compounds. This thesis focuses on 
the analysis of amyloid beta (Aß) proteins which are found to be strongly correlated with 
Alzheimer’s disease (AD) progression. The developments accomplished to improve 
detection sensitivity of MALDI MSI in the analysis of proteins and peptides will be able 
to provide a wealth of information to propel our understanding of disease onset and 
pathology, as well as to further the understanding of drug transport in order to aid in drug 
design.  
The thesis begins with an overview of MALDI MS and the technical elements of this 
technique, followed by details regarding the application of MALDI MSI. Difficulties of Aß 
analysis, and the significance of this protein in regards to AD are outlined. Chapter 3 
focuses on the development of a sample preparation protocol in the MALDI MSI detection 
for a small peptide. The ability of MALDI MSI in the detection and analysis of lipids and 
metabolites have been well reported in the last decade of MALDI MSI development. 
However, the capabilities of proteins and peptides detection using this technique are still 
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fairly limited. Therefore, we begin our study of MALDI MSI by investigating a dipeptide, 
ZP1609. Optimization and modifications to sample preparation protocols were employed 
in order to detect ZP1609 within intact mouse brain sections. In chapter 4, the focus then 
shifts to the study of the Aß peptide. Variations in sample preparation techniques, and the 
ability for MALDI MS detection of different Aß fragments were reported.  MALDI MSI 
developments outlined in chapter 3 were then applied to the analysis of Aß in chapter 5. 
Issues of poor signal resolution, and detection sensitivity were encountered. Solid-phase 
extraction using magnetic beads was attempted to enhance signal detection capabilities of 
MALDI MSI. 
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Chapter 3: Matrix-Assisted Laser Desorption/Ionization 
Mass Spectrometry Imaging of Intraperitoneally 
Injected Danegaptide (ZP1609) for Treatment of 
Stroke-Reperfusion Injury in Mice 
  
92 
 
 
3.1 Introduction 
3.1.1 MALDI MSI Analysis of Small Peptides 
Visualization of biological systems provide a platform to unravel and understand the 
complexities of cells, disease pathology and drug pathways. The molecular specificity of 
mass spectrometry imaging (MSI) and the “soft” ionization source, has made matrix-
assisted laser desorption/ionization (MALDI) MSI a powerful, emerging tool for imaging 
intact biological tissue samples [1-3]. The specificity and sensitivity mass spectrometry 
provides allows it to be used as a new technology for directly mapping and imaging intact 
biological tissue sections [4-6]. Current imaging techniques for biological specimens have 
contributed greatly in the study of biological systems, and the practice of medicine, but a 
common limitation resides in the inability for untargeted monitoring of multiple analytes 
simultaneously without introduction of labels or structural modifications to the system [7]. 
MALDI MSI can overcome this limitation by monitoring thousands of molecules within 
one experiment in order to study the spatial arrangement within tissue sections [8-9]. This 
technique is capable of localizing proteins, peptides, lipids, metabolites and small 
molecules in situ [10-11]. The data acquired can help shape our understanding of biological 
functions and diseases in order to improve current methods of treatment and prevention.  
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3.1.2 Biological Significance of Danegaptide (ZP1609) 
It is estimated that over 600,000 Canadians will be suffering from the effects of stroke by 
the year 2038 [12]. Stroke occurs when there is restricted blood flow to the brain resulting 
in loss of oxygen and neuronal cell death [13-14]. These infarctions result in debilitating 
effects, such as mobility limitations, chronic pain, vision problems, and excessive fatigue 
which impact the lives of not only the patients, but also puts extensive strain on the 
caregivers [15]. Antiarrhythmic drugs like rotigaptide (ZP123) were originally described 
to protect against cardiac ischemia-reperfusion injury as it exhibited protection in ischemic 
conditions [16-19]. Further development of ZP123 produced ZP1609 which exhibited 
similar effects as its parent compound, but it has the additional advantage of improved oral 
bioavailability making it a stronger candidate clinically [20-22]. When assessing the 
protective properties of ZP1609 in pre-clinical models of stroke-reperfusion injury, results 
demonstrated a decrease in infarct size when ZP1609 was administered prior to the 
reperfusion phase following ischemic conditions [14, 21, 23-24]. However, a current 
limitation to using ZP1609 as a neuroprotective agent for stroke, is a clear understanding 
on the ability of the dipeptide to target the brain itself. Blood brain barrier (BBB) 
permeability is essential for potential drug candidates in drug discovery programs. The 
BBB is designed to protect the central nervous system from toxins and pathogens, but this 
characteristic also acts to restrict the delivery of drugs to the brain [25-27]. Visualization 
of drug distribution can be achieved through radiolabeling drug derivatives, but this method 
is susceptible to false positives and is expensive to execute [28]. More importantly, the 
labels can potentially change the property of a small drug molecule. MALDI MSI provides 
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a label-free method capable of visualizing distribution of drug molecules within tissue 
sections. The ability to visualize BBB permeability of ZP1609 will give a better 
understanding of drug transport, toxicity, and help to predict potential off-target effects to 
advance development. This method is effective, yet requires experimental optimization, 
such as matrix selection and tissue washing to successfully detect the analytes of interest.  
ZP1609 has a monoisotopic mass of 291.12 Da, consisting of a benzamide group attached 
to amino acid residues proline and glycine (Figure 3.1). Investigation of the BBB 
permeability of ZP1609 using MALDI MSI can help advance our understanding of the 
neuroprotective properties of this compound against ischemic stroke. With MALDI MS, 
the matrix helps to transfer the laser energy for the “soft” ionization of analyte molecules 
and facilitate their detection, but even so, fragmentation still occurs especially for small 
peptides like ZP1609. Ideally, MALDI MS is capable of the direct analysis of ZP1609 from 
the complex background of biological tissues while simultaneously searching for possible 
fragments and adducts of ZP1609. Within this work, we demonstrate MALDI MSI 
capabilities in the direct detection of an intraperitoneally (IP) injected small peptide, 
ZP1609 within intact tissue sections as well as provide visual confirmation of the 
dipeptide’s successful penetration of the BBB.  
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Figure 3.1  ZP1609 dipeptide has a monoisotopic mass of 291.12 Da. This dipeptide 
consists of a benzamide group attached to proline and glycine amino acid residues. 
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3.2 Experimental 
3.2.1 Apparatus 
All MALDI MS sample analyses were performed on a Sciex TOF TOF 5800 MALDI mass 
spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser system (Ontario, 
Canada). The TOF TOF Series Explorer and Data Explorer were used for data acquisition 
and processing respectively. The Sciex TOF TOF Imaging software was used for region 
selection and image data collection. All MALDI MSI data was processed and analyzed 
using MathWorks MATLAB MSiReader software. 
Matrix sublimation was accomplished using a glass sublimator built in-house. Spray matrix 
application was applied using HTX Technologies automated TM Sprayer system (Chapel 
Hill, NC). CryoStar NX50 from ThermoFisher Scientific (Ontario, Canada) was used for 
all tissue slicing. Syringes and Needles used for sample preparation were purchased from 
Dyna Medical (Ontario, Canada), and Becton-Dickinson & Co (Franklin Lakes, NJ) 
respectively. Rehydration chambers were created with Fisherbrand Petri Dishes from 
Fisher Scientific (Ontario, Canada) and rehydration was achieved using a Robbins 
Scientific Micro Hybridization Incubator Model 2000 (San Diego, CA). Deionized water 
used throughout these experiments were obtained from a Millipore Milli-Q A10 Water 
Purification System (Bedford, MA). 
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3.2.2 Samples and Reagents 
All ZP1609 standards were supplied by Dr. Christian Naus from the University of British 
Columbia. Reagent grade acetonitrile (ACN), ammonium hydroxide, ethanol, and 
methanol were purchased from Caledon (Ontario, Canada). HPLC grade trifluoroacetic 
acid (TFA) was purchased from Fischer Scientific Ltd. (Hampton, NH). 2, 5 – 
dihydroxybenzoic acid (DHB), sinapinic acid (SA), chloroform, ammonium citrate dibasic, 
and acetic acid were purchased from Sigma Aldrich (St. Louis, MO). Phosphoric acid was 
obtained from EM Science (Darmstadt, Germany), and trifluoroacetic acid (TFA) was 
purchased from Fischer Scientific (Ottawa, ON, Canada). 
 
3.2.3 Treatment Conditions for Tissue Samples 
All procedures were approved by the Animal Care Committee of the University of British 
Columbia. Wildtype C57Bl/6 mice from the Jackson laboratory (Maine, USA) aged 3-4 
months were used. Transient Middle Cerebral Artery Occlusion (tMCAO) was performed 
according to the protocols of Lee et al. and Maniskas et al. [29-30]. Briefly, the mice were 
anesthetized with sodium pentobarbital (65 mg/kg IP) and given an opiate, buprenorphine 
(0.1 mg/kg). A local analgesic, bupivacaine (0.1 mL at 0.25%), was administered at the 
incision site prior to surgery. The mouse’s head was immobilized in a stereotaxic frame to 
allow exposure and blockage of the middle cerebral artery. The mouse brain was subjected 
to anoxic conditions for 1 hour followed by reperfusion of the blood supply. Following 
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injections of treatment compounds at designated time intervals, the mice were anesthetized 
using a lethal dose of sodium pentobarbital (120 mg/kg IP) and transcardially perfused with 
phosphate-buffered saline (PBS). The brains were removed and frozen at - 80 oC.  
The treatment paradigm was as follows: 1) Sham – saline brains; saline was IP injected and 
brains were removed 1 hour after injection. 2) Sham – ZP1609 brains; ZP1609 was IP 
injected and brains were removed 1 hour after injection. 3) Stroke – saline brains; tMCAO 
with reperfusion after 1 hour; saline was injected 10 minutes before reperfusion IP and 
brains were removed 1 hour later. 4) Stroke – ZP1609 brains; tMCAO subjected brains 
with reperfusion after 1 hour and ZP1609 was IP injected 10 minutes before reperfusion. 
Brains were removed 1 hour later. 5) Stroke – saline brains; tMCAO subjected brains with 
12 hours delayed extraction brains; saline was injected 10 minutes before reperfusion by 
IV, followed by IP injections every consecutive hour for 3 hour. The brains were removed 
after 12 hours. 6) Stroke – ZP1609 brains; tMCAO subjected brains with 12 hours delayed 
extraction; ZP1609 IV injected 10 minutes before reperfusion followed by IP injections 
every consecutive hour for 3 hours. Brains were removed after 12 hours. 
 
3.2.4 Tissue Preparation for MALDI MSI Analysis 
Tissue samples were mounted onto the tissue holder of the cryostat with water, and coronal 
sections were obtained to 14 μm thicknesses at - 25 oC. Each tissue section was 
approximately 5.5 – 9 mm by 7 – 9 mm in size. Once sliced, the sections were thaw 
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mounted onto indium tin oxide (ITO) coated glass slides and placed in a desiccator for 10 
minutes.  
A six step wash first using, 70% ethanol, and 100% ethanol was employed. This was 
followed by a mixture of 60% ethanol, 30% chloroform, and 10% acetic acid. Finally, 
another 100% ethanol, water, and 100% ethanol was used. The wash steps fix the tissue 
sections, as well as removes unwanted contaminants, salts and lipids. Upon tissue 
acidification, the water wash was replaced with 0.2% TFA. The tissue was incubated in this 
solvent at room temperature for 2.5 minutes. 
 
3.2.5 MALDI MSI Analysis 
DHB matrix was prepared to 20 µg/µL in 20% EtOH, 15% 100 mM ammonium citrate, 
and 1% phosphoric acid. When sublimated, 210 mg of DHB was used and sublimated at a 
temperature of 130 OC for a duration of 4 minutes. DHB was also applied onto sample 
sections using the automated TM sprayer from HTX Technologies (Chapel Hill, NC). 
Complete sample coverage was obtained using 8 passes at a velocity of 1200 mm/min, and 
a flow rate of 0.05 mL/min. A final matrix density of 3.33 x 10-2 mg/mm2 was achieved. A 
final rehydration step was performed using a 5% acetic acid solution. The sample slide was 
placed in the rehydration chamber at 70 oC for 3.5 minutes.  
The MALDI MS sample analyzed in the positive ion, reflectron mode. A total sum of 600 
shots/spot, and 30 shots/spot for spectral and imaging data acquisition respectively with a 
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1 kHz OptiBeam On-Axis Nd:YAG laser system. The open source MSiReader software 
was used for imaging data manipulations and analysis. 
 
3.3 Results and Discussion 
3.3.1 Identification of Danegaptide Peaks  
We first determined the sensitivity of MALDI MS for the detection of intact dipeptide, 
fragments, and adducts. Of the common matrices, 2,5-dihydroxybenzoic acid (DHB) has 
been found to be more susceptible to in-source decay, therefore making detection of 
ZP1609 fragments, along with corresponding salts and adduct formations possible [31-32]. 
Images for the intact peptide, along with confirmed fragments, salt ions, and adducts help 
to validate the data in order to show MALDI MSI capabilities in targeting analysis of small 
peptides in complex biological samples. Identification of ZP1609 standards was achieved 
using MALDI MS peaks of fragment ions, salt ions, and adducts listed in Table 3.1. As a 
result of the presence of salts within the complex samples, Na+ and K+ ions were commonly 
detected within the sample. Cleavage of glycine and proline also generated detectable 
peaks within the targeted m/z range of 100 – 550. 
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Table 3.1  Peaks identified through MALDI MS analysis of standard ZP1609 samples were 
recorded. These peaks include dipeptide fragmentation as well as any salt ions, and adducts 
formations detected within the m/z range of 100 – 550. 
 
 
Description Ion m/z 
[Glycine – H + Na +K]+ 135.96 
[Proline – H + 2Na]+ 160.03 
[M – C2H4NO + 2H]+ 235.11 
[M – CO2 + H3O]+ 266.14 
[M – CO2 + K]+ 286.14 
[M+H]+ 292.13 
[M + 2H]+ 293.14 
[M + Na]+ 314.13 
[M + K]+ 330.13 
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3.3.2 Effects of Variation in Matrix Selection  
The sensitivity of detection for the target m/z range of 100 – 550 for standard matrices 
sinapinic acid (SA), and 2,5 – dihydroxybenzoic acid (DHB) was then assessed for MALDI 
MSI within intact mouse brain tissue sections. Although α-cyano-4-hydroxycinnamic acid 
(CHCA) has been shown to be effective for low mass peptide analysis, CHCA generates 
an abundance of matrix background signals of high signal intensity within the 100 – 500 
range and thus CHCA peak intensities suppressed the ZP1609 signal. Although SA is 
normally used for analysis of small proteins, both DHB and SA matrices have been found 
to be highly effective for MALDI MSI analysis, therefore both matrices were tested for 
ZP1609 analysis [33-34]. For matrix comparisons, brain tissue samples from the 
experimental group with IP injected ZP1609 were coated with either SA or DHB and 
profiling data were collected (Figure 3.2). Among these two matrices, DHB was found to 
provide the greatest detection sensitivity of the target analytes with minimal interference 
from background. The majority of peaks observed with SA resulted from the matrix itself, 
while use of DHB allowed for detection of [M + H]+ peaks.  
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Figure 3.2  ZP1609 signal detection capabilities of SA (A), and DHB (B) were compared 
to select the most suitable matrix for image application. SA generated little to no analyte 
signals in comparison to DHB. This was further proven when data was collected with focus 
on the targeted m/z region 280 – 300. The [M + H]+ peak at m/z 292.13 was identified when 
DHB was used for analysis. 
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3.3.3 Effects of Tissue Washing in Signal Detection 
Following determination of matrix and target m/z for analysis, optimization of MALDI 
imaging parameters was explored. Standard sample preparation protocols for MALDI MSI 
of proteins and peptides for fresh frozen tissue sections include, tissue extraction, 
mounting, fixation, wash, matrix application and rehydration [7]. Salts and lipids cause a 
signal suppression effect on the targeted proteins and peptides so additional fixation and 
washing steps are required for the detection of target proteins and peptides in MALDI MSI 
[35-36]. As a result of these sample preparation procedures, compromises in signal and 
spatial resolution, as well as delocalization of target analytes are often observed when 
imaging proteins and peptides. Changes in these imaging parameters together contribute to 
a reduction in image quality when compared with MALDI MSI of lipids. Even though 
current sample preparation protocols commonly used in our research group have been 
devised for lipid imaging generating high resolution lipid images, there is still room for 
improvement when imaging proteins and peptides which typically requires salt and lipid 
removal by tissue washing. As such, in this study we assess and optimize sample 
preparation methods for IP injected dipeptides using ZP1609 as the analyte of interest. With 
peptides of such a low molecular weight (MW) range, tissue washing procedures must be 
monitored closely to determine whether sample loss poses as a critical factor for signal 
detection. Wash protocols vary greatly depending on the target analytes that are being 
investigated. The six step wash protocol was adopted from the Caprioli research group and 
was modified to maximize efficiency for our target analyte [36]. The six washes were 
intended to first fix the tissue with ethanol to prevent further degradation, followed by 
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removal of lipids and salts. The ethanol, chloroform and acetic acid mixture serves as a 
means of lipid removal while a water wash removes excess salts from the tissue section. 
Each step of the wash protocol helps to remove the endogenous contaminants that may 
hinder desorption and ionization of peptides. Effects of peptide detection following the 
wash protocol was clearly displayed in Figure 3.3. These wash conditions show significant 
enhancements in detection sensitivity and the signal-to-noise ratio when investigating the 
[M + H]+ peak at 292.13.  
 
3.3.4 Effects of Variation in Methods of Matrix Application 
The most widely used forms of matrix application are sublimation or automated spraying. 
Sublimation provides a means of matrix application without involvement of solvents thus 
minimizing the chances of additional adduct formation, as well as eradicating the 
possibility of delocalization producing an image of high spatial resolution [37]. The 
compromise that comes with sublimation is the reduction in analyte extraction capabilities 
resulting from the lack of solvent interactions to aid in the co-mixing of target analytes and 
matrix. When the two matrix application methods were compared for the detection of the 
small peptide ZP1609, it was clear the automated sprayer provided greater detection 
sensitivity as well as better signal-to-noise providing an image of greater structural details 
(Figure 3.4). Although the rehydration step aids in analyte extraction, when analyzing 
small, low abundance peptides, sublimation still appears to be inferior to matrix sprayers 
in analyte extraction efficiency. This deficiency resulted in images of poor signal and 
spatial resolution in comparison to the sprayer.  
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Figure 3.3  An abundant amount of lipids and salts were present on the surface of the tissue 
section resulting in signal suppression effects of the [M + H]+ peak (m/z 292.13) for ZP1609 
(A). Upon removal of the excess salts and lipids through the wash protocol, detection of 
the target analyte was achieved (B). 
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Figure 3.4  The [M + H]+ peak of ZP1609 at m/z 292.13 was used to assess extraction 
capabilities for small MW, low abundance peptides. Sublimation was used as a dry matrix 
application technique (A), this was compared to a wet application technique through use 
of an automated sprayer (B). The lack of solvent to facilitate extraction of target analytes 
resulted in poor signal-to-noise ratio hence compromising detection sensitivity and spatial 
resolution of the images obtained. 
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3.3.5 Acidification Effects on Signal Detection Sensitivity 
Through optimization of sample preparation protocols, we were able to detect ZP1609, but 
there was room for improvement in the images obtained. Therefore, increased acidification 
during the wash protocol was tested for its ability to enhance image resolution for low MW 
peptides. During the wash protocol, TFA was added to the water wash for excess salt 
removal. The tissue was washed for an extended period of 2.5 minutes in this TFA solution 
to allow for sufficient acidification of the tissue sample. This acidification process coupled 
with rehydration after matrix application using a 5% acetic acid solution resulted in greater 
signal detection capabilities as well as an image of greater spatial resolution (Figure 3.5). 
The maximum signal intensities detected per image have been displayed for direct 
comparison.  
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Figure 3.5  The [M + H]+ peak of ZP1609 at m/z 292.13 was used to assess the effects of 
extended acidification in extraction capabilities. To facilitate acidification, the water wash 
used for salt removal (A) was replaced with 0.2% TFA solution (B). Sensitivity of detection 
was improved when the tissue washing protocol was modified to include an extended 
acidification step allowing for higher signal intensity as well as identification of greater 
structural differentiation within tissue when target m/z values were assessed. 
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3.3.6 MALDI MSI Analysis of Intraperitoneally Injected ZP1609  
Using the above mentioned sample preparations methods, different experimentally treated 
mice brain samples were compared. Mice underwent four different surgical conditions 
(sham-saline, sham-ZP1609, stroke-saline, and stroke-ZP1609) in order to determine the 
efficiency of ZP1609 in penetrating the BBB to reach the brain parenchyma. Several 
fragment ions were targeted in order to validate the MALDI MSI data obtained was a result 
of the presence of ZP1609, and not by-products of the protocols. These fragment ions were 
previously determined when standards of ZP1609 were analyzed. Targeted m/z values 
were, 160.03, 266.14, 314.13, and 330.13 and these peaks correlate directly with, [Proline 
– H + 2Na]+, [M – COOH + H2O]+, [M + Na]+, and [M + K]+ respectively (Figure 3.6). 
When analysing saline injected tissue in comparison to the ZP1609 injected tissue, it was 
clear that the targeted peaks were detected with greater signal intensity. The most intense 
signals were detected from tMCAO subjected mice brains that underwent ZP1609 peptide 
injection in ischemic conditions followed by reperfusion. ZP1609 was found to exhibit 
similar protective behaviours as its parent ZP123 by countering the reduction of 
conductance efficiency under ischemic conditions. Therefore, a greater presence of 
ZP1609 was expected when treatment groups were subjected to tMCAO conditions. These 
speculations were supported by the data presented in Figure 3.6. When comparing ZP1609 
injected vs. tMCAO & ZP1609 injected tissue sections, a clear increase in signal intensity 
was observed. 
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Figure 3.6  MALDI MSI was able to detect low concentrations of IP injected ZP1609. 
Analysis of the fragment and salt ions, help reinforce the data suggesting the dipeptide’s 
successful penetration of the blood brain barrier. 
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With the optimized protocol and added tissue acidification procedure, tissue samples from 
different treatment groups were analyzed and found MALDI MSI signal detection was 
sensitive enough to differentiate between treatment groups. Two negative controls were 
provided, one with saline IP injected in normal conditions, while the other was injected 
with saline in ischemic conditions followed by reperfusion. The sample preparation 
protocol was then tested using samples from treatment groups which followed the protocols 
of current preclinical trials. This protocol differed in multiple ZP1609 injections were 
administered before reperfusion as well as after in 1 hour intervals. The tissue extraction 
was then delayed 12 hours following reperfusion in order to provide ample time so ZP1609 
can be efficiently transported across the BBB. If ZP1609 is effective in penetrating the 
BBB, then continuous drug delivery should permeate the brain allowing greater signal 
intensity to be observed and in turn provide a greater signal-to-noise ratio. The images 
generated from this sample group possessed greater spatial resolution and signal intensity 
(Figure 3.7). 
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Figure 3.7  Saline and ZP1609 was administered pre and post reperfusion in one hour 
intervals for the control and treatment groups respectively. Analysis of target ZP1609 
fragment and salt ions generated images of higher spatial resolution and signal intensity. 
The extended incubation period provided additional time for the dipeptide to permeate the 
brain tissues resulting in a greater signal detection for each fragment analyzed. 
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3.4 Conclusion 
MALDI MSI shows the benefits of tissue acidification to enhance detection sensitivity and 
overall image resolution. Analysis of ZP1609 using MALDI MSI shows the specificity of 
sample preparation parameters required to obtain successful images of small peptides 
within tissue sections. These parameters require optimization in order to cater to analytes 
under investigation. Through manipulations of the preparation protocol, we were able to 
obtain data that uncovers the capabilities of ZP1609 in successful penetration of the BBB. 
MALDI MSI has shown to be a useful technique for drug detection in intact tissue sections. 
This demonstrates the ability of the technique to provide important information regarding 
drug transport to help further develop ZP1609 as a means of pharmaceutical intervention 
in minimizing effects of stroke-reperfusion injury. 
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Chapter 4: Detection of Amyloid Beta Oligomeric 
Composition Using Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry (MALDI MS) 
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4.1 Introduction 
Alzheimer’s disease (AD) is now considered the most common cause of dementia, and the 
6th leading cause of death in the United States with over 5 million North Americans 
suffering from this disease [1]. The adverse neuropsychiatric and behavioral symptoms 
patients suffer from pose as a significant strain on our health care system, and give rise to 
socioeconomic issues. Hallmarks of the disease include extracellular plaques characterized 
by the accumulation of protein-containing deposits primarily consisting of amyloid beta 
(Aß) peptides and intracellular neurofibrillary tangles caused by aberrant phosphorylation 
of tau [2-4]. Previous work found these large fibrillary Aß structures within neuritic plaques 
killed cultured neurons [5]. This and other evidence led to the amyloid cascade hypothesis 
(ACH) which originally postulated that these insoluble fibrillary aggregates were the 
primary cause of neurodegeneration in AD patients [6]. Although extensive research has 
targeted these plaques, poor correlation between neurological deficits and plaque 
accumulation have been observed in AD patients [7-8].  
Recent studies have shifted focus to examine the onset of Aß aggregation from the 
monomeric peptides to the soluble form of Aß multimeric complexes, and found evidence 
linking the accumulation of the Aß oligomers to the progression and severity of AD, in 
particular, with long term hippocampal, age-onset memory failures [2-3, 9-12]. Due to 
these recent findings, modifications to the amyloid cascade hypothesis have been made to 
target the role of soluble Aß oligomers in disease progression [13-15]. In healthy 
individuals, Aß peptides are degraded within or cleared from the brain [16-17]. Reduction 
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in the degradation or clearance efficiency results in accumulation of the soluble oligomers 
that correlate with disease onset and progression. Understanding the mechanisms and 
effects of Aß oligomerization in the brain is therefore critical to the development of novel 
therapeutics for AD. A common experimental approach is the in vitro toxicity essay of Aß 
oligomers on neuron cell cultures, where cellular viability is quantified to determine the 
effects of various forms of Aß and/or potential therapeutics [18-22]. The Aß samples for 
the in vitro experiments are typically obtained from commercial sources. Numerous 
protocols have been reported for in vitro oligomeric Aß1-42 preparations with the largest 
variation residing in the monomerization and oligomerization solutions used [23-26]. 
Surprisingly, to our knowledge, comprehensive studies examining the effect of protocol 
conditions on the resulting oligomer size distribution are not available in the literature to 
our knowledge. In addition, it is not a common practice to verify the composition of the 
Aß oligomers prior to use, partly due to the limitations in techniques available for fast and 
simple Aß multimer characterization.  
Currently, the most common means for oligomer quantification is gel electrophoresis [27]. 
The technique depends on the ability for SDS to bind to proteins of interest. This binding 
compromises the structural integrity of proteins resulting in dissociation of oligomer 
composition [28]. Low sample throughput and prevalence of gel smearing are also 
significant issues which act as limitations in resolution and possess accuracy issues [29]. 
Another prominent issue gel electrophoresis possesses is the inability to accommodate for 
a large mass range for multimer analysis. The percent composition of acrylamide within 
the gel is tailored for the target sample. The larger the peptide or protein under analysis, 
the lower the amount of acrylamide used in order to facilitate appropriate separation to 
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obtain distinct bands. For samples containing a wide range of molecular weights, the set 
acrylamide concentration could not optimally accommodate for both extremes, resulting in 
either the smaller molecular weight peptides to run off the gel, or poor resolution of the 
larger peptides. Other techniques available to study Aß aggregation include atomic force 
microscopy (AFM), surface plasmon resonance (SPR), absorbance and fluorescence [30-
31]. AFM is generally suitable for detection of large Aß aggregates such as fibrils, but not 
the soluble small oligomers. SPR is typically used to detect interactions in amyloid-ligand 
binding, but ligand interaction is not selective enough to differentiate oligomers by size. 
Likewise, absorbance and fluorescence can detect the bulk presence of oligomers, but lacks 
the ability to differentiate between small size differences of Aß oligomers.  
Electrospray ionization mass spectrometry (ESI MS) has been widely used as an alternative 
label free tool for Aß analysis [32-34]. ESI is capable of transforming the multimeric forms 
of amyloidogenic peptides from solvated to gaseous ions as intact non-covalent complexes 
[35]. However, the resulting complex ions can possess a wide range of multiple charges; 
for example, z = 2 to 10. Oligomers of different sizes can therefore have identical m/z, 
making the peak assignment to oligomer sizes a perplexing task [36-37]. To overcome this, 
researchers turned to the use of ion mobility spectrometry (IMS), which can resolve the 
multimeric complex ions, not only by m/z, but also according to size based on their mobility 
in a drift tube [38-40]. In recent years, the combination of IMS with ESI MS has become 
an invaluable tool in deciphering the assembly mechanism of Aß oligomers [28, 39, 41-
45]. While IMS-MS is extremely powerful, the resulting two-dimensional data of drift time 
and m/z generally require interpretation by IMS specialists. Hence, its applications remain 
limited in the neuroscience community.  
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The work described herein focuses on a simpler mode of MS based on matrix assisted laser 
desorption ionization (MALDI). In contrast to ESI, MALDI generates gaseous ions of 
peptides and proteins predominately in the singly charge state (z = 1). As a result, the 
measured m/z values of Aß oligomers directly represent the mass of the oligomers. To our 
knowledge, Van Duyne et al. presented the first use of MALDI MS to detect oligomers of 
Aß1-42, but the use of MALDI MS was not the focus of their work, and only one mass 
spectrum of the oligomers was presented as a supplementary figure [46]. Also, the adoption 
of this application has not been observed in the literature. Most importantly, the authors 
did not present validation experiments to confirm that the observed Aß complex ion 
distribution indeed reflect that of original oligomeric Aß sample solution. In the work 
described herein, we will examine the validity of MALDI MS in measuring the 
composition of Aß multimers. Particularly, we aim to rule out the non-specific associations 
of Aß peptides, either during sample preparation or during the MALDI process, which 
could produce artificial Aß complexes non-existent in the original sample. To achieve this, 
we manipulated the size distribution of Aß oligomer samples using molecular weight cut 
off filters, and subsequently illustrated the expected changes in the resulting MS data. After 
validating MALDI MS in measuring Aß multimeric composition, the method has been 
applied to examine the Aß samples prepared using published protocols on monomerization 
and oligomerization for in vitro toxicity assays.   
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4.2 Experimental 
4.2.1 Apparatus 
Aß samples were filtered using 10 kDa and 30 kDa MWCO filters purchased from Pall 
Corporation (Ann Arbor, MI), followed by use of Centrifuge 5417c from Eppendorf 
(Westbury, NY). ThermoFisher Scientific NanoDropTM Spectrophotometer 2000c 
(Waltham, MA) was used to assess the final filtrate concentration of Aß samples after 
filtration. All MALDI MS sample analyses were performed on a Sciex TOF/TOF 5800 
MALDI mass spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser 
system (Ontario, Canada). All microscopy data was acquired using a Nikon Eclipse Ni-E 
microscope with fluorescent filters and a DS-Qi2 monochrome microscope camera. ImageJ 
software was used to process and analyze the data collected. Statistical comparisons 
between experimental groups were performed using the GraphPad Prism software. A  two-
way ANOVA with Tukey’s HSD test was applied. 
 
4.2.2 Samples and Reagents 
All Aß peptides were purchased from Bachem (King of Prussia, PA). Ethanol, methanol, 
and acetonitrile (ACN) were purchased from Caledon (Ontario, Canada), and hexafluoro-
2-propanol (HFIP), dimethyl sulfoxide (DMSO), Sinapinic acid (SA), trypsin, 
amphotericin B solution, 7% poly-L-ornithine from Sigma Aldrich (St. Louis, MO). 
Phosphate buffered saline (PBS) was purchased from Quality Biologicals (Gaithersburg, 
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MD). Ham’s F-12 nutrients mixture, B27 supplement, N2 supplement, 
penicillin/streptomycin, glutamax, and 4’-6-diamidino-2-phenylindole (DAPI) were 
purchased from Life Technologies (Grand Island, NY). Formic acid, ammonium hydroxide 
was obtained from EM Science (Darmstadt, Germany), and trifluoroacetic acid (TFA) was 
purchased from Fischer Scientific (Ottawa, ON, Canada). Neurons were isolated from 
Wistar rats purchased from Charles River (Montreal, QC, Canada), Hank’s balanced salt 
solution (HBSS) and neural basal media from Wisent (St. Jean-Baptiste, QC, Canada), 
Trypsin inhibitor from Roche Life Sciences (Indianapolis, IN) and propidium iodide (PI) 
was purchased from Biotium (Hayward, CA). 
 
4.2.3 Amyloid Beta Sample Preparation 
Aß peptides were suspended in one of the lyophilization solvents (NH4OH, TFA, HCO2H, 
or HFIP) at a concentration of 1 mM to facilitate monomerization. To prepare for short 
term storage, the sample was fractionated in 10 μL aliquots and lyophilized for 1 hour at   
– 100 oC and stored at – 80 oC. To prepare for use, each aliquot of lyophilized powder was 
resuspended in 10 μL of DMSO and sonicated in a 37 oC water bath for 10 minutes. The 
sample was then brought to a concentration of 150 μM with the selected incubation solvent 
(F12, PBS, or H2O) and vortexed. The solution was incubated at 4oC for 24 hours to 
facilitate oligomerization.  
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4.2.4 Molecular Weight Cut-Off Filtration 
Aß samples monomerized in NH4OH followed by resuspension in either PBS, or H2O were 
used for MWCO Filtration assessments. Aliquots of 70 μL were pipetted into each filter 
and centrifuged 4 times in 30 second intervals at 14 000 rpm with Centrifuge 5417c from 
Eppendorf (Westbury, NY). Once filtered, 1 µL of each sample filtrate was pipette onto the 
NanoDropTM spectrophotometer. The A280 protein/peptide analysis software was used to 
assess the concentration of each filtrate through monitoring the absorbance at wavelength 
(λ) 280 nm. MWCO Filters at 10 kDa and 30 kDa were purchased from Pall Corporation 
(Ann Arbor, MI).  
 
4.2.5 Amyloid Beta Toxicity for Embryonic Rat Cortical Neuron Cultures 
Aß samples lyophilized in NH4OH and resuspended in DMSO and F12 medium to 150 µM 
was used. An Aß1-42 sample was prepared and incubated for 24 hours while a second sample 
was prepared at the time of use providing the oligomer and monomer conditions 
respectively. Three different environmental conditions were provided for each cell 
population (n = 4) with 10 μL additions of pre-incubated Aß1-42 (monomer), and post 
incubation Aß1-42 (oligomer). One set of cultures were left without any environmental 
alterations to provide a baseline (control) of the natural decrease in cellular viability over 
time. The cells were incubated for 6, 24, 36, and 48 hours. PI staining was applied through 
addition of 10 μL of PI 45 minutes prior to fixation. The cells were fixed with 500 μL of 
4% formaldehyde followed by 400 μL of 2% formaldehyde. The fixing agent was removed 
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with 3 consecutive 1x PBS washes. Fine tweezers were used to plate the cells fixed on 12 
mm round cover slips. The cells were counter-stained with DAPI for nuclear visualization 
and imaged were acquired at 20x magnification. Five images were acquired for each cell 
culture in order to obtain the average cell deaths vs. total cells per culture.  
 
4.2.6 MALDI MS Analysis 
SA matrix was prepared to 10 µg/µL in 50% ACN and 0.05% TFA. The Aß sample and SA 
matrix were deposited as sandwiched layers, where 0.75 μL of the Aß solution was spotted 
between two layers of SA (0.75 μL). The spots were washed twice with 1 μL water prior 
to analysis. The TOF TOF Series Explorer in positive ion linear mode and Data Explorer 
were used for data acquisition and processing respectively.  
 
4.3 Results and Discussion 
4.3.1 MALDI MS Detection of Aß1-42 and Aß1-40 Oligomer Composition 
We began our studies by reproducing the detection of Aß oligomers with MALDI MS based 
on the conditions reported by Van Duyne [46]. Briefly, hexafluoro-2-propanol (HFIP) and 
F12 medium were respectively the monomerization and oligomerization buffers. Sinapinic 
acid (SA) was the MALDI matrix, and the same spotting was used with a modification of 
including a washing step. Effects of different TFA concentrations in the matrix solution 
was assessed, and we concluded that a reduction in TFA concentrations was most beneficial 
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in the detection of oligomers within the sample. This coincides with previous studies 
indicating low pH disruptions in the formation of non-covalent complexes [47-48]. The 
instrument’s acquisition parameters were set to optimize for detection sensitivity.  
Additional to studying oligomers from Aß1-42, we also included the commonly studied Aß1-
40. Similar results confirming the successful detection of Aß oligomers of various sizes 
were observed for both Aß1-40 and Aß1-42. The mass spectra from Aß1-40 and Aß1-42 oligomers 
are shown as Figure 4.1. The monomeric Aß1-40 and Aß1-42 peptides have a molecular 
weight of 4329.86 Da and 4514.10 Da respectively. Doubly charged monomers and trimers 
were not observed, the mass spectrum therefore displayed signals from singly charged ions 
from monomers up to 7-mer and 11-mer when the full mass range up to 50 kDa was 
acquired for Aß1-42 and Aß1-40 respectively. Compared to the prior report on MALDI MS 
results of Aß oligomers [46], the same overall trend in oligomer size distribution was 
detected. Specifically, the monomer and dimer signals were the strongest with the dimer 
peak slightly higher in intensity. The signals dropped off in a similar decay fashion for 
larger complexes, although higher peak intensities from the larger oligomers were shown. 
Differences in sensitivity could be attributed to the different MALDI mass spectrometers 
used. The MALDI results also generally agree with those reported by gel electrophoresis, 
where substantial quantities of multimers relative to the monomer were typically detected, 
as bands of similar size and darkness. The sensitivity was however much higher for 
MALDI MS, as it required only 0.5 g per run, compared to the typical 190 – 100 g per 
run in gel electrophoresis. When compared to ESI MS, rather different looking mass 
spectra were reported with similar samples. A dominant peak corresponding to the 
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monomer, with a 3 charge state, is typical in the ESI spectra of Aß1-42. The sum of all 
oligomeric peaks were only a minor part of the total response [42].  
 
4.3.2 Validation of MALDI MS Detection Capabilities 
To prepare for MALDI MS analysis, sample solutions were mixed with laser absorbing 
matrices, deposited as microliter-volume droplets on target plates, and allowed to dry. 
Hence, a common concern in the MALDI MS characterization of complexes is the 
possibility of artificial non-specific associations during drying. In the literature, numerous 
examples of MALDI MS application on complexes of biomolecules were reported and 
reviewed [47, 49-50]. The consensus is that the technique is capable of detecting certain 
non-covalent multimeric complexes under optimized conditions. However, there is not one 
universally optimal protocol. Therefore, it is important to experimentally verify that the Aß 
non-covalent complexes detected by MALDI MS herein were not an artifact caused by 
non-specific associations that occurred either during sample spot drying or within the mass 
spectrometer in gas phase. 
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Figure 4.1  Mass spectra of oligomers prepared from Aß1-42 (A-B) and Aß1-40 (C-D) 
displayed singly charged ions upon analysis of the full mass range (A, C). Exclusion of the 
monomer (B, D) resulted in oligomers up to 50 kDa in mass observed. 
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4.3.2.1 Analysis of Aß Fragments with Various Propensities for Oligomerization 
To achieve this, modified Aß1-40 samples with different oligomerization propensities used 
in toxicity experiments were investigated. Oligomerization of wild-type Aß1-40 sample was 
compared to a scrambled Aß1-40 sequence, and (Gln22) Aß1-40 (Figure 4.2). Scrambled Aß1-
40 samples are used in AD research as inactive controls, and therefore does not have an 
affinity for oligomerization [51]. In contrast, (Gln22) Aß1-40 (E22Q) is a mutation which 
replaces Glu22 with Gln22, this mutation of Aß was found to aggregate more readily in 
comparison to the wild-type peptide [52-55]. The resulting MS data presented in Figure 
4.2 reflect the reported variation in oligomerization affinities. Focus was placed starting 
from the expected m/z of the dimer in order to focus comparison on oligomer composition 
within samples. Through comparison of these three peptide samples, minimal 
oligomerization limited to presence of a dimeric peak was detected for scrambled Aß1-40 
peptide, while the E22Q mutation clearly presented a much higher propensity for 
oligomerization in comparison to the wild-type. 
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4.3.2.2 Molecular Weight Cut-Off Filtration Analysis 
Additional validation was achieved through manipulation of the Aß1-40 oligomer 
composition by passing them through molecular weight cut-off (MWCO) filters at either 
10 kDa or 30 kDa cut-off points. The 10 kDa cut-off filter should in theory remove 
complexes larger than dimers (8659.72 Da). The resulting mass spectrum indeed revealed 
the expected reduction in signals from the large oligomers (Figure 4.3). A moderate 
suppression of the dimer signal was also observed. In comparison, when the Aß1-40 
oligomers were filtered at the 30 kDa cut-off point, the monomer to dimer and trimer ratios 
were largely unchanged. Signal reduction was observed for tetramer (m/z 17,320.44) and 
larger species. Taking into account of non-specific adsorption and imprecision in filter cut-
off points, the collective MS results were found to be in agreement with the expected 
changes in oligomer composition resulting from the MWCO treatments.  
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Figure 4.2  Oligomerization of wild-type Aß1-40 (A) was compared to scrambled Aß1-40 
(B), and mutated (Gln22)  Aß1-40 (C). Through comparison, modifying Glu
22 with Gln22 in 
the peptide sequence resulted in an Aß1-40 peptide which aggregates much more readily 
while the scrambled version of the peptide produced minimal to no oligomerization. 
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Figure 4.3  Mass spectra of oligomerized Aß1-40 after passing through 10 kDa (A) and 30 
kDa (B) filters. Prior to filtration, oligomeric peaks up to 50 kDa were observed. After 
filtration, peaks detected correlate directly with the filter size used. 
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The effects of reduction in sample concentration following MWCO treatments were 
addressed through determination of final filtrate concentration followed by serial dilutions 
of standard Aß1-40 samples. The filtrate concentration was found to be approximately three 
times lower than stock concentrations. Respective dilution of stock samples were analyzed 
and a full range of oligomers were detected (Figure 4.4). This allowed us to draw the 
important conclusion that, despite the harsh, non-native, nature of MALDI MS, it is capable 
of revealing the oligomeric composition of Aß complexes in solution. The results in Figure 
4.3 did not support any significant levels of non-specific associations of Aß. The Aß 
complexes detected by MALDI closely agreed with expected oligomeric compositions of 
the solution samples. Finally, the intensity of the MALDI MS signals of these oligomers 
corresponded to their concentration at least in a semi-quantitative fashion. It is however 
noteworthy that the detection of very large Aß oligomers, if present, is limited by the 
sensitivity of the MS. 
  
135 
 
 
 
Figure 4.4  Oligomer samples of Aß1-40 were prepared and diluted to 50 µM 
concentrations. Oligomer detection was not compromised from dilutions indicating loss of 
sample during filtration process would not result in results obtained.  
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4.3.3 Effects of Variations Among Amyloid Beta Preparatory Protocols 
Having established MALDI MS to be a technique that can gauge the composition of Aß 
oligomers, we aim to further demonstrate its capability as a quality control methodology 
that monitors the on-set of in vitro Aß oligomerization. As previously mentioned, there are 
several published protocols of in vitro preparation of Aß oligomers [56-62]. All of them 
involve the two major steps of; firstly, solubilizing the lyophilized Aß as presumably 
monomers; and secondly, incubating the samples for oligomer formation. However, a 
noticeable difference among published protocols is the choice of solvents or solutions in 
facilitating these two monomerization and oligomerization steps. Yet the assessment of 
possible differences in the resulting samples has not been reported to our knowledge. 
Hence, we conducted the investigation with MALDI MS, first looking at the effect of the 
monomerization condition followed by that of the oligomerization condition. 
 
4.3.3.1 Monomerization Solvents 
The purpose of the monomerization step is to break up previously formed Aß clusters, and 
in turn, to promote the formation of ß sheets upon oligomerization. Aß has a high affinity 
for oligomerization as a result of the hydrophobic amino acid composition. When in 
aqueous environments, aggregation provides the stability needed therefore making the 
initial monomerization a crucial step preceding oligomerization. The Aß clusters must be 
broken apart prior to the formation of the desired ß sheets of the oligomer structure. The 
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commonly used solvents or solutions are, hexafluoro-2-propanol (HFIP), HCO2H, and 
trifluoroacetic acid (TFA). Acidic solvents provide the low pH which disrupts the 
quaternary structure of non-covalent complexes. HFIP, HCO2H, and TFA are believed to 
remove Aß non-specific aggregates and fibrils within a sample [63]. In addition, we also 
included NH4OH in this studies, which was believed to promote monomerization of Aß 
and thus others have recently adopted its use [24-25, 59-60]. To begin our assessment, four 
Aß samples were prepared with each of these four solvents and lyophilized. MALDI MS 
analysis was then performed on the resulting “monomerized” Aß samples. To enhance the 
sensitivity in the detection of the non-covalent complexes, the spectra were re-acquired 
beginning at 6500 Da for the purpose of reducing the suppressing effects from the 
saturating signals of the monomer. The mass spectra shown in Figure 4.5 were each 
normalized to its monomer intensity. The results revealed that significant amounts of 
multimers were present in the “monomerized” samples prepared from all three of the most 
commonly used protocols (HFIP, HCO2H, and TFA). The oligomeric complexes were most 
noticeable from samples prepared with HFIP and HCO2H. Only the Aß sample prepared 
with NH4OH resulted in predominantly monomers. This somewhat unexpected finding 
illustrates the importance of verifying the Aß composition prior to use. 
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Figure 4.5  Mass spectra of Aß1-40 after treatment with four monomerization solutions: 
HFIP (A), HCO2H (B), TFA (C) and NH4OH (D). To enhance the sensitivity in the 
detection of the larger oligomers, the upper spectra were acquired beginning at 6500 Da 
for the purpose of reducing the suppressing effects from the monomers.  
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4.3.3.2 Oligomerization Solvents 
The effect of the oligomerization condition on Aß oligomer composition was examined 
next. Among the published protocols, PBS and Ham’s F12 medium were most widely used 
in oligomeric Aß preparation [46, 58, 61, 64]. Additional to these two solutions, we also 
included the use of deionized water in the comparison. Using these three oligomerization 
solutions, we performed incubation on each of the four samples monomerized by HFIP, 
HCO2H, TFA and NH4OH. Our MALDI MS results revealed a substantial degree of 
oligomerization across all four samples, in all three oligomerization solutions. The four 
sets of mass spectra were essentially indistinguishable from one another, and so only the 
results from the HFIP-monomerized sample are shown as an example (Figure 4.6). HFIP 
was selected as it was most commonly used in literature. The oligomer distributions from 
the three oligomerization solutions in Figure 4.6 were not distinctly different from each 
other. Hence, we concluded that the choice of the oligomerization solvent/solution was not 
a critical factor to the extent of oligomer formation. We believe that Aß favors the 
oligomerized state due to the protein’s hydrophobic characteristics, and therefore 
oligomerization proceeded spontaneously and favorably regardless of the choice of solvent 
or solution. However, the critical factor resides in the incubation period needed to facilitate 
the formation of oligomers. When compared with MS results prior to incubation, 
significantly stronger signals from multimers were observed following incubation.  
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Figure 4.6  Mass spectra of oligomerized Aß1-40 prepared in two oligomerization 
solutions, PBS (blue) and F12 (green), and in water (red). 
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4.3.4 In Vitro Amyloid Beta Toxicity Assessment 
Aside from determining which monomerization or oligomerization conditions work best 
for Aß, the more critical message of this work is the importance of experimentally verifying 
the composition of Aß multimers prior to use. In this case, all three of the most commonly 
used monomerization protocols actually resulted in significant amounts of Aß oligomers; 
namely a 20-25% dimer to monomer ratio was observed after monomerization, which 
overlaps with 25-30% ratio observed after oligomerization. Given that the oligomeric form 
of Aß is mainly responsible of its deleterious effect on neurons, the use of such false Aß 
“monomers” would have led to results conflicting with the literature. To illustrate this 
point, data from an in vitro toxicity assay on embryonic rat cortical neuron cell cultures are 
presented. The average cell death percentage was determined in 48 hours under the 
treatment of Aß oligomers and the verified Aß monomers prepared by NH4OH, and a 
control of no treatment was also included (Figure 4.7). The results obtained from the 
monomer treatment were indistinguishable from the control in all time points measured. In 
contrast, an accelerated rate of cell death was observed upon treatment with Aß oligomers. 
At 24 hours, the toxicity of the oligomer sample treatment began to display a notable 
difference when compared to the monomer sample (P = 0.07). As the treatment was 
extended for 36 hours, the toxicity of the oligomer treatment was significantly higher than 
that of the control (P = 0.002). Once the treatment was carried out for 48 hours, statistically 
significant differences in toxicity between the oligomeric sample and that of the control 
and monomeric samples were observed (p = 0.03 and 0.01 respectively). In the literature, 
reports on the effect of Aß oligomers varied depending on conditions such as cell culture 
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preparation methods, stains, and dosage. For example, one reported a decrease in cellular 
viability from 90% to 55% upon exposure to Aß oligomers while another reported 20% 
cellular viability after 48 hours [65-66]. Importantly, our results reaffirmed the significant 
toxicity of the oligomeric form of Aß, in comparison to the monomeric Aß and the control, 
and MALDI MS played an important role of rapid validation of Aß sample composition 
for the toxicity experiments. 
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Figure 4.7  Rat cortical neuron cell death determined under the treatment of Aß1-42 
monomers and oligomers. Results are presented as the mean with S.E.M. (n=4). *: P ≤ 
0.05, **: P ≤ 0.01 (two-way ANOVA with Tukey’s HSD test). 
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4.4 Conclusion 
In this work the capabilities of MALDI MS as a sensitive, fast, and simple method in the 
detection of in vitro Aß oligomers was demonstrated. The results were validated through 
use of MWCO filters to ensure the MS data reflects the sample composition in solution. 
The methodology allowed us to investigate the effect of preparation conditions on the 
resulting monomeric/multimeric composition, particularly in tracking the onset of 
oligomerization by monitoring the formation of 2-mer to 10-mer. In terms of applications, 
MALDI MS allows researchers to quickly characterize their Aß multimeric composition 
prior to studying their role in neurodegeneration, and/or evaluating potential 
neuroprotective agents against Aß. The importance of quality control on the Aß 
composition was demonstrated through an in vitro toxic assay on neuron culture, where 
MALDI MS played a critical role in identifying a fully monomerized sample of Aß. Finally, 
the detection of Aß oligomers with MALDI MS presents an exciting opportunity for ex 
vivo characterization of Aß extracted from the brain, or direct MALDI MS imaging of 
multimeric Aß in brain tissues, although further research and development is required to 
overcome the potential issue of background interferences and signal suppression.  
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Chapter 5: Enhancements in Detection Sensitivity for 
the Amyloid Beta Protein with Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry Imaging 
(MALDI MSI) 
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5.1 Introduction 
5.1.1 MALDI MSI of Proteins in Intact Tissue Sections 
The development of MALDI matrix application methods has come a long way. From 
initially pipetting a large droplet of matrix to cover the target sample area, to the 
development of automated sprayers, these advancements and innovations have made it 
possible to obtain images of high spatial and signal resolution for lipids, and small 
molecules [1-6]. This technique can provide information regarding spatial distribution for 
a wide range of analytes within a single sample, as well as provide a means for untargeted 
analysis of complex tissue sections [7-11]. Although much progress has been made in the 
development of MALDI MSI, limititations still exist in the detection sensitivity for low 
abundance analytes within biological samples. In comparison to lipids and other small 
molecules, intact proteins are more difficult to extract form tissue sections making imaging 
of proteins a more challenging task in comparison.  
Integration of MALDI MSI into the proteomics field has been hindered by the poor 
detection sensitivity of low abundant proteins and peptides within the complex molecular 
composition of each tissue sample [12]. The high concentrations of salts, lipids, and 
metabolites in comparison cause ion suppression effects, and therefore development of 
sample preparation methods becomes critial in determining the success or failure of these 
imaging experiments. Ion suppression results from numerous competing factors that can 
have a negative effect on the extraction, desorption, and ionization of target analytes within 
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a sample [13]. There are two types of sample related ion suppression effects with MALDI 
MS, matrix suppression, and analyte suppression [14]. However, matrix suppression poses 
as a greater effect when analyzing compounds with a lower m/z. Therefore, when looking 
at proteins, understanding sample composition and identifying compounds that could cause 
ion suppression of your target analyte is of greater importance. Expansion and development 
of suitable sample preparation techniques along with determination of appropriate 
instrumental parameters can assist in the detection of intact proteins within tissue samples.  
The analysis of Aß1-42 has been proposed to address the difficulties in the detection and 
localization of this protein. Aß1-42 is a small, hydrophobic protein with a mass of 4514.10 
Da. The complications in working with Aß experimentally is caused by its instability in 
aqueous conditions which lead to rapid aggregation. Here, focus has been placed on 
enhancements in detection sensitivity of the intact Aß1-42 proteins through use of solid-
phase extraction techniques. We aim to utilize magnetic C18 beads as a means for Aß 
extraction, while simultaneously retaining the Aß distribution within intact brain sections. 
 
5.1.2 Magnetic Bead Solid - Phase Extraction 
Solid - phase extraction (SPE) has become one of the most commonly used sample 
preparation techniques for isolation, and enrichment of target analytes [15]. This technique 
helps to isolate analytes from complex mixtures which may possess compounds that could 
prevent the detection and analysis of the target analyte. SPE has gained popularity as a 
result of its simple execution protocols, and the reduction of solvents needed for sufficient 
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extraction [16-17]. In comparison to liquid - liquid extraction techniques, SPE delivers a 
more efficient separation providing higher recovery of analytes [18]. Traditionally, SPE 
techniques involve a stationary phase, and a mobile phase consisting of the analyte mixture. 
Efficient analyte isolation or enrichment is dependent on the selection of a suitable 
stationary phase. The various types of SPE available are: reverse phase, normal phase, and 
ion exchange [19]. With reverse phase (RP) SPE, the stationary phase is nonpolar while 
the mobile phase is polar. RP SPE is most suitable when the target analyte is a moderate to 
nonpolar compound which can be retained on the stationary phase until a nonpolar solvent 
is used for elution. Normal phase (NP) SPE is the opposite, with the stationary phase being 
polar while mobile phase is nonpolar, therefore targeting polar analytes. With ion exchange 
SPE, the main interaction is based on the electrostatic attraction of a compound's charged 
functional groups with the charged groups bound to the silica surface of the stationary 
phase.  
In this work, we use RP SPE to facilitate extraction of Aß from the brain tissue surface in 
order to enhance the sensitivity of MALDI MSI. RP SPE should be highly effective for the 
hydrophobic Aß proteins, however traditional SPE columns would not be useful in this 
instance since the samples of interest are intact brain tissue sections. Instead, the 
application of loose magnetic beads directly on tissue sections has been proposed. 
Magnetic beads provide an alternative to chromatography columns, spin columns and pipet 
tip sample preparation techniques [20-21]. In theory, the beads will extract hydrophobic 
proteins such as Aß off from the tissue surface, while the application of the organic matrix 
solvent will cause the proteins to essentially “elute” off of the beads. This process should 
improve the efficiency of the co-crystallization process between Aß and the matrix. In 
153 
 
terms of sample preparation, magnetic beads can be fixed in a stationary position with a 
magnet, while tissue washing procedures are performed to remove unwanted contaminants. 
This prevents loss of the protein during preparatory steps prior to analysis, and will also 
preserve the anatomical locaton of target analytes allowing for a more rigorous tissue 
washing approach. Overall, this technique should improve the resulting detection 
sensitivity of proteins like Aß within intact tissue for MALDI MSI analysis. 
 
5.2 Experimental 
5.2.1 Apparatus 
All MALDI MS sample analyses were performed on a Sciex TOF/TOF 5800 MALDI mass 
spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser system (Ontario, 
Canada). The TOF TOF Series Explorer and Data Explorer were used for data acquisition 
and processing respectively. The Sciex TOF TOF Imaging software was used for region 
selection and image data collection. All MALDI MSI data was processed and analyzed 
using MathWorks MATLAB MSiReader software. 
Matrix was applied using HTX Technologies automated TM Sprayer system (Chapel Hill, 
NC). A CryoStar NX50 from ThermoFisher Scientific (Ontario, Canada) was used for all 
tissue slicing. Syringes and Needles used for tissue sample preparation Aß injections were 
purchased from Dyna Medical (Ontario, Canada), and Becton - Dickinson & Co (Franklin 
Lakes, NJ) respectively. Rehydration chambers were created with Fisherbrand Petri Dishes 
from Fisher Scientific (Ontario, Canada), and rehydration was accomplished using a 
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Robbins Scientific Micro Hybridization Incubator Model 2000 (San Diego, CA). A High 
Performance BH airbrush was purchased from Iwata (Portland, OR) for all airbrush 
applications. Deionized water used throughout these experiments were obtained from a 
Millipore Milli-Q A10 Water Purification System (Bedford, MA). 
 
5.2.2 Samples and Reagents 
Reagent grade acetonitrile (ACN), ammonium hydroxide, and methanol were purchased 
from Caledon (Ontario, Canada). HPLC grade ethanol, acetone, and trifluoroacetic acid 
(TFA) were purchased from Fischer Scientific Ltd. (Hampton, NH). Ammonium hydrogen 
phosphate (AP), α-cyano-4-hydroxycinnamic acid (CHCA), ß-casein, chloroform, 
ammonium citrate dibasic, acetic acid, anhydrous dimethyl sulfoxide (DMSO), and 
sinapinic acid (SA) were purchased from Sigma-Aldrich (St. Louis, MO). Phosphate 
buffered saline (PBS) was purchased from Quality Biologicals (Gaithersburg, MD). Ham’s 
F-12 nutrients mixture was purchased from Life Technologies (Grand Island, NY). 4700 
calibration mass standards kit was purchased from Applied Biosystems (Foster City, CA). 
The Aß1-42 protein was purchased from Bachem (King of Prussia, PA). C18 beads BcMag, 
Zip Tips, Dynabeads were purchased from BioClone Inc. (San Diego, CA), Millipore 
(Billerica, MA), and Life Technologies (Oslo, Norway) respectively. Pentobarbital Sodium 
Injections were purchased from Bimeda MTC Animal Health Inc. (Ontario, Canada). 
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5.2.3 Amyloid Beta Sample Preparation 
Aß1-42 peptides were suspended in NH4OH and brought to a concentration of 1 mM to 
facilitate monomerization. To prepare for short term storage, the sample was fractionated 
in 10 μL aliquots, lyophilized for 1 hour at – 100 oC, and stored at – 80 oC. For each use, 
an aliquot of lyophilized powder was resuspended in 10 μL of anhydrous DMSO, and 
sonicated in a 37 oC water bath for 10 minutes. The sample was then brought to a 
concentration of 150 μM with Ham’s F-12 medium, and vortexed for 30 seconds. The 
solution was incubated at 4 oC for 24 hours to facilitate oligomerization. 
 
5.2.4 Variations in Magnetic Bead Extraction Efficiency 
Three C18 beads were tested for in-vial extraction efficiency (Figure 5.1). C18 Dynabeads 
were assessed along with BcMag and Zip Tips. The 4700 calibration mixture, ß casein 
digest, and Aß1-42 samples were used for the assessments. 10 µL of 0.1 µg/µL was prepared 
for each sample. 10 µL of each stock bead solution was added to individual epitubes, and 
10 µL of each sample was added to corresponding tube and mixed. A binding period of 2 
minutes was provided followed by application of magnet to allow for supernatant 
removal. 10 µL of wash solution (0.1% TFA) was added and aspirated with a micropipet. 
The beads were held constant once again and supernatant removed. After three washes, 6 
µL of desorption solution (50% ACN) was added. The mixture was aspirated and 
remained at room temperature for 2 minutes followed by removal of the supernatent. This 
sample procedure was applied for both BcMag and Dynabeads. The media for Zip Tips 
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were contained within 10 µL pipette tips. In order to test the binding efficiency, the tips 
were wet with a 50% methanol solution, and equilibrated with a 0.1% TFA solution. Each 
sample was aspirated 10 times using individual Zip Tips, followed by aspiration of the 
wash solution (0.1% TFA). The proteins and peptides were then eluted with a 60% 
acetonitrile solution.  
  
157 
 
 
 
 
Figure 5.1  In-vial binding efficiency of BcMag and Dynabead magnetic beads were tested. 
Magnetic Beads were added into the sample vial, followed by a binding period. After 
which, the beads were held in place by a magnetic, and the supernatant was removed. The 
beads were washed three times, followed by addition of an elution buffer to “elute” the 
target analytes off of the beads. The resulting solution was then spotted on a MALDI MS 
sample plate and analyzed. 
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5.2.5 Magnetic C18 Dynabeads on Plate Extraction Efficiency  
To test bead compatibility with MALDI MS analysis, 25 µM concentration of Aß1-42 was 
premixed with CHCA, and 0.75 µL was spotted on the plate. A second layer of C18 
Dynabeads was spotted on top. 12.5 µg/µL stock solution of Dynabead was diluted 5x, 
10x, and 15x with water and 0.75 µL of each dilution was spot on a premixed analyte-
matrix spot to assess optimal bead concentration for spot analysis. On plate Aß extraction 
potential was evaluated by spotting 0.75 μL of 25 µM, 2.5 μM, and 0.25 μM Aß on a 
MALDI plate. Once dried, 0.75 μL of 1.25 μg/μL of Dynabeads were spotted above each 
sample spot. CHCA was prepared to 5.5 μg/μL in 50% ACN, 6 mM AP, 0.1% TFA, and a 
final layer of CHCA was then spotted.  
 
5.2.6 Sample Preparation for MALDI MSI Analysis 
5.2.6.1 Tissue Extraction and Postmortem Amyloid Beta Injections 
Transgenic and wildtype Fischer (344) rats were used for these experiments. Once deeply 
anaesthetized, rats were euthanized with a pentobarbital overdose, and brain tissue was 
extracted using a fresh frozen extraction method [22]. With this method, the rat brain was 
not perfused with 4% paraformaldehyde prior to Aß injection, therefore the blood flow to 
the tissue was retained. Immediately after tissue removal, the brain tissue was placed on 
dry ice and 25 µL of 150 uM Aß solution was injected directly into the cerebral cortex. As 
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the syringe was withdrawn, small amounts of sample solution was continuously released 
to ensure Aß is present along the entire sagittal section. This guarantees analyte presence 
with each coronal tissue section. Once injection was completed, tissue was completely 
frozen on dry ice and stored in – 80 oC or sectioned using a cryostat for immediate MALDI 
MSI analysis. 
 
5.2.6.2 Tissue Mounting and Preparation 
Tissue samples were freeze mounted onto the tissue holder of the cryotostat with water and 
sectioned to 14 μm thickness at - 25 oC. Once sectioned, the coronal brain sections were 
thaw mounted onto ITO glass slides and placed in a desiccator for 10 minutes. A six step 
tissue fixation, wash and acidification procedure was performed. The samples were first 
washed by submerging in 70% EtOH solution, followed by 100% EtOH for 30 seconds 
each. The slide was then removed and placed for 2 minutes in a solution of 60% EtOH, 
30% chloroform, and 10% glacial acetic acid. This was followed by a 30 seconds wash of 
100% EtOH. Acidification was achieved through submerging the sample within a solution 
of 0.2% TFA for 2.5 minute. A final wash was done using 100% EtOH to remove residual 
solvent and water. 
 
5.2.6.3 On Tissue Magnetic Bead Extraction 
The stock Dynabead solution was diluted to 1.25 µg/µL with Millipore H2O to make a 3 
mL solution. The solution was vortexed for a minute to facilitate dispersion. 0.75 µL of the 
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Dynabead solution was pipet onto spiked Aß samples on top of tissue sections for spot 
analysis. 1 mL of the Dynabead solution was deposited into the solvent holder of the 
airbrush. Airbrush application was used to evenly coat the entire tissue section with the 
Dynabead solution. 4 layers were applied with a 30 seconds wait period in between each 
layer.  
 
5.2.6.4 Matrix Deposition & Tissue Rehydration 
SA matrix was prepared to 10 µg/µL in 50% ACN, and 0.05% TFA Solution. SA was 
sprayed onto tissue sections using the TM sprayer. Complete sample coverage was obtained 
using 4 passes at a velocity of 1200 mm/min and a flow rate of 0.1 mL/min. The 
temperature and pressure were held constant at 70 oC and 12 psi respectively with a 30 
second wait period between layers. A final matrix density of 1.67 x 10-3 mg/mm2 was 
achieved. When magnetic bead extraction was performed, an additional layer of matrix 
solvent was sprayed at a reduced flow rate of 0.05 mL/min. Tissue rehydration was 
performed using a 5% acetic acid solution. A metal heat sink was fixed onto the top half of 
a petri dish, the sample slide was then fixed onto the heat sink. This portion of the petri 
dish was placed in a rehydration chamber set to 70 oC for 30 seconds. A filter paper soaked 
in the 5% acetic acid solution was placed on the bottom half of the petri dish. The top and 
bottom halves were then sealed together and placed in the rehydration chamber for 3.5 
minutes.  
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5.2.7 MALDI MSI Parameters 
The Sciex TOF TOF imaging software was used to select for regions of interest (ROI). 
Once selected, acquisition parameters were selected for the positive ion mode. Protein and 
peptide data were acquired in linear and reflectron modes respectively. Images were set up 
to a raster size of 70 µm and a total of 35 shots was performed at each fixed sample position.  
 
5.3 Results and Discussion 
5.3.1 Enhancement of Detection Sensitivity Facilitated by C18 Magnetic 
Bead Extraction   
5.3.1.1 Magnetic Bead Selection  
In vial assessment of variations in binding capabilities among C18 beads from Millipore, 
BioClone Inc, and Life Technologies was performed. Extraction capabilities of the beads 
were tested using 0.1 µg/µL samples of ß-casein digest, 4700 calibration peptide mixture, 
and Aß1-42. Through comparison, Dynabeads showed to be superior in the binding and 
elution capabilities for the scope of samples tested. Of the three beads, BcMag presented 
the worst retention and elution capabilities for all samples, with poor binding capabilities 
for the Aß sample resulting in the majority of the analyte residing in the supernatant. 
BcMag was only capable of recovering three out of five of the peptides within the 4700 
calibration mixture. While the ZipTips were great with the recovery of smaller peptides, 
Aß samples were not able to elute off of the beads, and therefore presented ion counts of 
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less than 100. In comparison, the Dynabeads were capable of recovering the widest range 
of samples with the highest recovery for all three samples tested. Therefore, the C18 
Dynabeads were selected for further analysis. The magnetic properties of the Dynabeads 
also provide an additional platform for control over the bead placements.  
Upon selection of the C18 Dynabeads, determination of bead concentration was required 
for uniform coverage without reduction of detected signal intensity. 12.5 µg/µL stock 
solution of Dynabeads was diluted 5x, 10x, 15x, 20x and spotted onto premixed sample-
matrix spots on a MALDI MS plate. The spectral data in Figure 5.2 revealed a 50% 
decrease in signal intensity when the beads were diluted greater than 10x.  
Microscopic images were obtained to visualize bead distribution on sample spots. Uneven 
bead dispersion was seen when bead concentration was diluted greater than 10x. Poor 
uniformity in bead coverage greatly affect extraction potential for the target sample 
throughout the entire section analyzed, and therefore uniform distribution must be taken 
into account when optimizing the concentration of beads required. Based on the 
microscopic images presented in Figure 5.3, both 5x and 10x dilutions presented fairly 
uniform coverage, since signal detection was seen to be relatively similar in intensity, a 
1.25 µg/µL concentration of Dynabeads was confirmed to be optimal for further 
applications.  
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Figure 5.2  Effects of varying Dynabead concentrations applied per sample spot was 
assessed. A stock solution of 12.5 µg/µL was diluted 5x (A), 10x (B), 15x (C), and 20x 
(D). Aß1-42 signals obtained was evaluated. A reduction of greater than 50% in signal 
intensity was observed when bead dilution exceeded 10x, therefore a minimum of 1.25 
µg/µL bead concentration per sample spot was determined.   
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Figure 5.3  The optimal concentration of C18 Dynabeads was evaluated by visualizing 
bead coverage on the sample spot. Upon Dilution of the 12.5 µg/µL stock solution 5x (A), 
10x (B), 15x (C), and 20x (D), 5x and 10x dilutions provided the most coverage throughout 
the entire sample section. 
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5.3.1.2 Aß Signal Enhancement Effects using C18 Magnetic Beads  
C18 Dynabeads utilized the principles of reverse phase chromatography (RPC) to capture 
hydrophobic proteins and peptides within mixtures. The beads possessed an iron oxide core 
which was coated with silica. The silica surface was modified with hydrophobic alkyl 
chains in which target proteins and peptides were bound. Once washed, the bead bound 
proteins were eluted into a clean solvent for analysis. Enhancement effects of the C18 
magnetic beads were tested using 0.25 µM, 2.5 µM, and 25 µM concentration of Aß1-42 
proteins. Each of these samples were spotted onto a MALDI MS sample plate in layered 
format along with 1.25 µM C18 Dynabeads, matrix, and solvent. A final layer of matrix 
solvent was spotted due to the enhancement effects observed in previous testing. The 
additional solvent layer was hypothesized to facilitate protein extraction, and the co-
crystallization of the matrix – anayte mixture. From Figure 5.4, minor signal enhancement 
effects were observed for concentrations 2.5 µM and 25 µM sample solutions, while 
significant enhancement was seen for the detection of the 0.25 µM Aß1-42 sample. A 
concentration of 0.25 µM was below the instruments detection threshold for Aß1-42, but 
with the help of magnetic bead extraction, a well resolved signal was observed.  
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Figure 5.4  On plate extraction of Dynabeads was assessed using different concentrations 
of Aß1-42, 0.25 µM (A-B), 2.5 µM (C-D), and 25 µM (E-F). MALDI MS spectra was 
obtained before and after bead extraction protocol was applied in order to compare signal 
enhancement effects. With Dynabead extraction, signal intensity detected was amplified 
for each concentration with the most significant being of the lowest, 0.25 µM 
concentration. On bare plate, an Aß concentration of 0.25 µM would have previously gone 
undetected without the aid of Dynabeads. 
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Following the enhancements observed through spot analysis of Aß on the MALDI MS 
sample plates, the detrimental effects of tissue surface composition on Aß signal detection 
was addressed by spotting Aß samples with the same concentration range of 2.5 µM – 25 
µM on untreated intact tissue sections. Spiked tissue sections were first analysed prior to 
direct injection of Aß in order to minimize possible complications such as sample diffusion 
within the brain. This allows the signal suppression and enhancement effects observed to 
solely be a result of the tissue background and Dynabeads respectively. Figure 5.5 presents 
the signal detection capabilities of MALDI MS with and without the Dynabeads. The 
abundance in molecules on the tissue surface resulted in poor S/N ratios. Without the 
Dynabeads, the contaminants on the tissue surface strongly suppressed the Aß signal to 
nearly undetectable levels. However, the Dynabeads were able to enhance signal detection 
of the target Aß protein for all concentrations tested. As expected, although enhancement 
was observed when Dynabead were used, the effects were severely compromised on tissue 
in comparison to when previously tested on the bare plate (Figure 5.4). When detected, the 
Aß signal was found to be shifted from 4514.10 Da to ~ 5000 Da. This shift is not 
uncommon when MS experiments are performed on tissue samples [23]. The three-
dimensional structure of these samples influence the ion flight time resulting in 
significantly lower resolution and mass accuracy. These effects become more and more 
pronounce the larger the target analyte is. Unfortunately, the height difference of the 
mounted tissue section can be minimized, but not completely eradicated. The tissue was 
also analyzed prior to any Aß sample spotting to ensure the peak observed at ~ 5000 Da is 
representative of the Aß sample. 
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The enhancement in signals observed support the prior hypothesis that the beads aid in the 
extraction of Aß proteins allowing for improved co-crystallization with the MALDI MS 
matrix. Significant enhancement effects were most prominent for low Aß concentrations 
on bare plate, and on tissue analysis of Aß. The issue of surface contamination when 
studying tissue sections can be minimized with additional tissue washing procedures. 
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Figure 5.5  On Tissue extraction capabilities of Dynabeads were assessed with 0.25 µM 
(A-B), 2.5 µM (C-D), and 25 µM (E-F) concentrations of Aß1-42. With the abundance of 
molecules on a tissue surface, the MALDI MS spectra displayed poor S/N ratio with a 
noisy baseline. Signal enhancement effects of Dynabead application was observed for each 
concentration tested. 
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5.3.2 Signal Enhancement Effects of Magnetic Beads for Amyloid Beta 
Using MALDI MSI  
Successful detection of Aß fragments and fibrils using MALDI MSI was previously 
reported, but improvements are still needed to increase image resolution for MALDI MSI, 
and to be able to detect intact Aß1-42 oligomers [24]. To achieve peak magnetic bead 
extraction efficiency, sample preparatory protocols were first optimized. Salts and lipids 
were first removed through serial tissue washes, but a balance must be attained to minimize 
delocalization of target analytes, yet still effectively remove enough endogenous 
contaminants for the detection of Aß. The ability to extract proteins from tissue sections 
was dependent on suitable matrix application protocols. In order to facilitate efficient 
extraction, a wet matrix application by means of an automated sprayer systems was used. 
The solvent provides a medium for the extraction of analytes in order to co - crystallize 
with the matrix for MALDI MS analysis. The spray parameters were tested and modified 
to offer the ideal compromise allowing for the greatest degree of analyte extraction with 
minimal levels of delocalization on the tissue surface. The choice of matrix used was also 
a limiting factor. The matrix must be suitable for a higher mass range to accommodate for 
the molecular weight of intact proteins, it must be soluble in organic/aqueous solvents, and 
possess small, unchanging particle size in order to provide a uniform coating on sample 
sections. Commonly used matrices are CHCA and SA. CHCA is generally applied when 
studying lower molecular weight proteins (< 5000 Da). SA is generally used for the 
investigation of proteins of >3500 Da, and therefore makes it more suitable for intact Aß 
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analysis. Previously, optimization of magnetic bead parameters have been achieved with 
CHCA due to its abilities to accommodate for a wide range of MW making it ideal for 
testing bead binding capabilities for a broad range of MW analytes. With the focus now 
switching to MALDI MSI of tissue sections, sinapinic acid (SA) was tested and revealed 
comparable results for Dynabead extraction efficiency. The solvent used for SA possessed 
the same organic : aqueous ratio of 50 : 50 and therefore would not alter elution capabilities.  
MALDI MSI data was collected for Aß1-42 and Aß1-40 presented in Figure 5.6. Once 
optimization and development of a suitable sample preparatory techniques in the tissue 
washing, matrix application, and rehydration protocols were achieved, the images showed 
dramatic improvements in Aß detection. Aß proteins were detected at the injection site for 
both, Aß1-40 and Aß1-42 samples using MALDI MSI (n = 4, n = 2 respectively). As a result 
of the high intensity signal at the injection site, anatomical features of the brain tissue were 
suppressed. Images obtained from wildtype rat brains showed weak levels of Aß along the 
visible length of the corpus callosum within the section, this was a result of the injection 
site located at the corpus callosum, and the high permeability of this region.  
Dynabeads were applied over the entire tissue section with an airbrush. Once dried, 
additional matrix and solvent layers were applied using the TM sprayer to help facilitate 
Aß extraction from the tissue section. From Figure 5.6, the MALDI MSI data obtained 
from tissue sections with Dynabead application showed a severe decrease in signal 
detection with only the injection site from the wildtype tissue with Aß1-42 injected visible. 
The spatial resolution of the images were found to be completely compromised, with a 
significant decrease in signal intensity. 
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In comparison to former MALDI MS analysis, the images did not correlate with the 
previous data obtained regarding Dynabead signal extraction. This was speculated to be a 
result of several contributing factors, including the aforementioned signal suppression 
effects, and the decrease in signal resolution and mass accuracy experienced when analysis 
is performed on the three-dimensional tissue sections. When an additional layer of beads 
were sprayed onto the tissue surface, this enhanced the negative effects of the uneven tissue 
surfaces. Although expected, the degree of impact this posed for the resulting image 
surpassed expectations. Additionally, image acquisition requires several hours to complete, 
within the vacuum system it is possible the beads detached, and fell off during the duration 
of this time period. Furthermore, additional precautions may be required to prevent 
potential Aß sample loss during the tissue washing procedures, and to increase extraction 
efficiency from the bead to co-crystallize with the matrix applied. 
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Figure 5.6  MALDI MSI of Aß1-40 and Aß1-42 tissue sections of wildtype and transgenic 
rats reveals presence of the target protein within the injection sites (circled in the images 
above). However, upon addition of C18 Dynabeads, enhancement effects were not 
observed. On the contrary, signal intensity and spatial resolution were both severely 
compromised. 
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5.4 Conclusion 
MALDI MSI has provides a platform for the localization of proteins and peptides within 
intact tissue sections. However, contaminants on tissue surfaces strongly reduced signal 
detection capabilities for Aß. The extraction power of C18 magnetic Dynabeads for Aß 
proteins were clearly observed for bare plate and on tissue MALDI MS analysis. When 
applied to MALDI MSI, a combination of factors including surface uniformity, and 
extraction efficiency contributed towards the inability to attain additional signal 
enhancement effects. 
Future work should focus on uncovering alternative substrates with Aß extraction potential, 
such as magnetic nanoparticles, and use of metal ions. Magnetic nanoparticles would aid 
in minimizing the negative impact that Dynabeads exhibited on the surface uniformity of 
samples analyzed. If successful, the magnetic properties of the nanoparticles would be 
beneficial in retaining spatial resolution when rigorous forms of tissue clean – up are 
utilized. Application of metal ions as a matrix could potentially eliminate the need for 
alternative substrates for extraction purposes. Both Zn2+ and Cu2+ have been found to bind 
to histidine residues of Aß proteins [25-26]. Additionally, both metals have been reported 
effective as a matrix, either in oxide form (ZnO), or as a modification of standard matrices 
(Cu-CHCA) [27-28]. If successful, not only will this technique benefit the field of 
Alzheimer’s research, it will help uncover a range of analytes upon tissue sections that may 
have previously gone unnoticed due to signal suppression effects. 
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6.1 Conclusions and Future Work 
Mass spectrometry (MS) is an incredibly powerful technique that has become an essential 
tool for the analysis of biological molecules and systems. Through the introduction of soft 
ionization techniques ESI and MALDI, it became possible for MS to identify intact 
proteins. MALDI MS offers a means to perform targeted and untargeted identification of 
the molecular weight, and amino acid sequence for proteins in a complex mixture. Current 
MALDI MS research has extended past its conventional analysis capabilities, and 
introduced a new dimension to sample analysis. Development of MALDI MSI provided an 
alternative platform for protein and peptide detection, where location information within 
an intact tissue section can be found. This presented the opportunity to utilize MALDI MSI 
to better understand biological systems, and disease pathology by simultaneously acquiring 
information regarding multiple analytes within a sample.  
Integration of MALDI MSI as a technique for biochemical imaging eradicates the 
uncertainties that exists with stains and labels used in traditional imaging methodology 
such as immunohistochemistry (IHC). This is pertinent in furthering research involving the 
pathology of disease like AD. The uncertainties that reside in disease progression along 
with the physical and chemical properties of the toxic Aß protein make it difficult to select 
stains and labels with high specificity. Unfortunately, Aß1-42 is the most relevant factor 
when discussing AD pathology, but its instability in aqueous conditions and its propensity 
for aggregation makes Aß challenging to work with in laboratory settings. Therefore new 
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technology in the detection of Aß would be greatly beneficial in the advancements of 
research in this field. 
The ability for MALDI MSI detection of peptides within complex tissue systems was first 
assessed using a low molecular weight dipeptide, ZP1609. Within tissue sections, the 
abundance of lipids and metabolites are readily ionizable, and therefore posed as a 
hindrance for peptide analysis due to ion suppression effects. The importance of tissue 
washing, acidification, and rehydration protocols was outlined in chapter 3. These tissue 
preparatory steps facilitated the removal of excess salts and lipids in order to reduce the 
suppression effects experienced by these contaminants when upon analysis. The addition 
of an acidification protocol presented significant enhancement effects in both signal 
detection and spatial resolution of the images acquired. Capabilities of MALDI MS as a 
fast and sensitive method in the detection of Aß oligomers was presented in chapter 4 of 
this thesis. This work presented MALDI MS as a label-free method for researchers to 
quickly characterize in vitro multimeric Aß composition prior to additional 
neurodegenerative studies.  
Through MALDI MS analysis of Aß, and the development of successful MALDI MSI 
tissue preparatory protocols for ZP1609, MALDI MS detection of Aß spiked on top of the 
tissue surface was assessed. As expected, the protein presented difficulty ionizing and 
desorbing off of the tissue section. Along with the challenges of ion suppression from salts 
and lipids, detection sensitivity of the low abundance Aß proteins were greatly diminished. 
Application of solid-phase extraction (SPE) techniques using magnetic beads facilitated 
the extraction of Aß samples off of the tissue section. Once the matrix was applied onto the 
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sample, Aß was able to successfully elute off of the beads and ionize providing signals of 
greater intensity. The magntic beads were able to enhance signal detection of low 
concentration Aß samples which were previously undetectable when pipet onto the tissue 
section. However, when extraction capabilities were tested using MALDI MSI on tissue 
samples injected with either Aß1-42 or Aß1-40, the results differed. The reduction in signal 
detection and spatial resolution of images acquired after application of the magnetic beads 
was hypothesized to be a result of the uneven tissue surface. When an additional layer of 
magnetic beads were applied onto the tissue section, the detrimental effects of the 
challenges experienced with the uneven surface of three dimentional tissues samples were 
amplified. Additionally, image acquisition for MALDI MSI requires several hours, the 
beads were speculated to potentially detach off of the MALDI sample plate during the 
acquisition process within the vacuum environment. 
The ability to perform solid-phase extraction of Aß prior to MALDI MSI analysis would 
be greatly beneficial in the ex vivo detection of Aß and understanding its correlations with 
AD pathology. Not only will these advancements aid AD research, it would be extremely 
useful in assisting the improvement of MALDI MSI detection sensitivity for all low 
abundant substances within tissue sections that may have previously gone unnoticed. 
Therefore, future work would revolve around development of alternative substrates with 
higher extraction potential, and better compatibility with MALDI MSI conditions. These 
can include the use of magnetic nanoparticles, or investigating the binding capabilities of 
Aß to metals such as zinc and copper ions.  
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In comparison to previously used Dynabeads, magnetic nanoparticles would provide a 
much smaller substrate for Aß extraction. The reduction in size will help to minimize the 
unavoidable effects of variations in surface uniformity tissue samples exhibit. This 
reduction will instead aid in generating a more even layer with fuller coverage of the entire 
sample section. Retaining the magnetic properties provide an advantage when additional 
tissue treatments and washes are require without compromising spatial resolution of 
analyte distribution.  
 Alternatively, the binding capabilities of Aß to metals such as zinc and copper ions can be 
exploited. Although Zn2+ levels in the extracellular regions of the brain are fairly limited, 
Zn2+ concentrations in brain regions most greatly affected by AD such as the hippocampus, 
amygdala, and cortex are relatively high [1-2]. Zn2+ bind to histidine residues on Aß 
proteins and peptides forming both 1 : 1, and 3 : 1 zinc(II)-Aß complexes [3]. This 
interaction induced rapid in vitro aggregation of Aß [2, 4-6]. Like zinc, Cu2+ was also found 
to interact with Aß by binding to the histidine residues. However, it was reported to form 
1 : 1 and potentially 2 : 1 Cu(II)-Aß complexes [7-8]. The binding capabilities of Aß to 
metal ions provides a great opportunity to utilize this interaction to enhance detection 
sensitivity. The use of metal ions Zn2+ and Cu2+ provide an added bonus in removing the 
necessity for an additional substrate appication for SPE, since both copper and zinc have 
been utilized successfully as either a modification to standard matrices (Cu-CHCA), or as 
a stand alone matrix (ZnO) [9-10].  
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